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SUMMARY 
 
Antibiotic resistance of many bacterial strains to current antibiotic treatment 
strategies  are  increasing.    Bacterial  biofilm  related  diseases  displaying 
resistance to current antibiotics is an area of intense investigations. Failure to 
eradicate  biofilm  forming  pathogenic  microorganisms,  coupled  with  an 
exacerbated host immune response results in extensive tissue damage and 
ultimately  chronic  inflammation  within  infected  patients.    Periodontitis  and 
cystic fibrosis (CF) represent typical forms of chronic inflammatory disease 
 
The  aim  of  this  study  was  to  evaluate  the  efficacy  of  a  newly  developed 
glycylcycline,  tigecycline,  against  non-pseudomonal  Gram-negative  CF 
pathogens  and  oral  pathogens  commonly  associated  with  inflammatory 
disease  of  the  lung  and  oral  cavity,  respectively.  Minimum  inhibitory 
concentrations (MICs) of periodontal and pulmonary pathogens in planktonic 
growth  phase  and  sessile  biofilms  were  determined  by  serial  doubling 
dilutions  with  tigecycline.    Furthermore,  planktonic  MICs  and  sessile  MICs 
exposed to tigecycline and a competitive efflux pump inhibitor MC-207,110 
EPI  were  assessed  by  XTT  assays.    In  addition  the  biomasses  of  sessile 
biofilms  exposed  to  tigecycline  and  EPI  were  determined  by  crystal  violet 
assay.    This  investigation  demonstrated  a  significant  improvement  in  the 
susceptibility of both planktonic and sessile cells to tigecycline following the 
addition of an EPI, indicating that the EPI enhanced sensitivity to antibiotic 
treatment of resistant bacterial strains.  Furthermore, bacterial biofilm biomass  
XIV 
 
of  the  CF  pathogen  Burkholderia  cepacia  was  reduced  significantly  by  co 
treatments of tigecycline and EPI. 
 
Finally, the immunomodulatory properties of tigecycline were evaluated using 
clinically  relevant  epithelial  cell  lines,  A549  OKF6-TERT2  and  a  primary 
neutrophil  cell  line.   Oral  and  pulmonary  cell  lines  were  co-inoculated  with 
subinhibitory  concentration  of  tigecycline  and  Escherichia  coli  derived 
lipopolysaccharide  (LPS).    The  neutrophil  cell  line  was  co-inoculated  with 
(phorbol 12-myristate acetate) PMA and tigecycline.  Epithelial IL-6 and IL-8 
levels were determined by ELISA and RT-qPCR, demonstrating only marginal 
down-regulation  in  some  cases  of  these  inflammatory  mediators.  However, 
tigecycline at subinhibitory concentrations did reduce the levels of IL-8 and 
MMP-9 synthesised by neutrophils in a dose dependent manner.  
 
In conclusion, tigecycline alone is ineffective at killing and reducing biomass of 
mature biofilms associated with chronic inflammatory disease of the lungs and 
oral  cavity,  however  the  addition  of  a  competitive  efflux  pump  inhibitor 
decreased  resistance  of  the  bacterial  biofilm  to  tigecycline.    This  would 
suggest  a  possible  new  chemotherapeutic  use  to  treat  patients  who  suffer 
from  a  chronic  inflammatory  disease.    Furthermore,  down-regulation  of 
inflammatory  mediators  by  subinhibitory  concentration  of  tigecycline  may 
indicate  a  potential  use  in  the  therapeutic  management  of  both  CF  and 
periodontal disease, and other diseases of chronic inflammatory origin. 
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1 Introduction 
1.1 Introduction to Cystic Fibrosis 
Cystic Fibrosis is the most common lethal autosomal recessive disease in the 
Caucasian  population.    CF  sufferers  currently  have  a  life  expectancy  of 
approx  33  years,  which  has  increased  over  the  last  40  years  when  life 
expectancy was previously confined to early childhood (Ye et al, 2001).  This 
increase  in  life  expectancy  is  due  to  improvements  in  areas  of  infection 
awareness  and  antimicrobial  treatment  strategies  (Chernish  et  al,  2003). 
Chronic infection and inflammation are the primary cause of morbidity and 
mortality in CF patients (Pilewski et al, 1999). CF is caused by a mutation in 
the  CF  transmembrane  conductance  regulator  (CFTR)  gene,  located  on 
chromosome 7q31 spanning approximately 230kb of genomic DNA containing 
27 exons (Harris, 1992). This gene was first identified in 1989 by the groups of 
Lap-Chee  Tsui  (Toronto,  Canada)  and  Francis  Collins  (Michigan,  USA) 
(Harris, 1992).  The mutation results in clinical manifestations including mucus 
plugging and obstruction of the respiratory and digestive tracts through over 
production of a dehydrated and thickened secretion (Serisier et al, 2009).   
 
The  commonest  clinical  symptom  of  CF,  and  most  debilitating,  is  chronic 
obstructive  lung  disease.  Deterioration  of  the  CF  lung  starts  in  the  upper 
lobes, which is in contrast to involvement of the lower lobes in pneumonia and 
bronchitis (Quinton, 1999).  Mechanisms underlying the early acquisition of 
infection in CF are complex and incompletely understood (Davies et al, 2009).  
In general, immediately after birth, bacteria colonise and infect the airways 
taking advantage of the impaired mucociliary action and secretions produced Chapter 1: Introduction 
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by  the  CF  lung.  This  provides  fertile  grounds  for  bacterial  growth  and 
colonisation (Chernish et al, 2003).   
  
1.1.2 Microbiology of the CF lung 
Understanding  the  genetic  trait  that  results  in  CF  is  just  as  important  as 
identifying the bacteria that infect the CF lung (Hearst et al, 1995).  In healthy 
individuals, inhaled bacteria are trapped by the mucus secretions that line the 
major airways. These bacteria are moved upward by mucociliary clearance 
and after swallowing are destroyed by stomach acids (Govan et al, 1996).  In 
the CF lung, bacterial clearance from the airway is hampered by viscid airway 
secretions,  resulting  in  bacterial  colonisation,  pulmonary  damage  and 
subsequently an exacerbated inflammatory response.  
 
The  most  frequently  reported  respiratory  pathogen  in  the  CF  lung  is 
Pseudomonas  aeruginosa  (Govan  et  al,  1996).  Greater  than  93%  of  CF 
patients are reported to have P. aeruginosa infections (Son et al, 2007).  P. 
aeruginosa  has  evolved a huge array  of  complex  strategies  to evade  host 
defences to ensure its survival (Davies et al, 2009). Indeed, more than 90% of 
mortality associated with CF results from infections by P. aeruginosa (Fink et 
al, 2003).  The phytopathogen Burkholderia cepacia, which is distantly related 
to  P.  aeruginosa  was  reported  to  cause  infections  in  3.5%  of  CF  patients 
worldwide (McClean et al, 2009).  
 
Burkholder  first  identified  B.  cepacia  in  the  1950s  identifying  it  as  the 
bacterium  commonly  associated  as  the  causative  agent  of  soft  onion  rot, Chapter 1: Introduction 
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which was later isolated as a virulent pathogen in CF sufferers in the 1980s 
(TomLin  et  al 2005).   By  the  early  1990s, multidrug  resistant  strains  of  B. 
cepacia emerged as a major infection control challenge for CF carers (Govan 
et al, 1996).  CF patients colonized by B. cepacia experience a rapid decline 
in lung function compared to those colonised with P. aeruginosa (McClean et 
al, 2009).  Once B. cepacia has been established in the CF lung, it is rarely 
eradicated with infection ranging from maintaining stable respiratory functions 
to rapid and often fatal clinical decline (McClean et al, 2009).   
 
Once bacteria are established in the CF lung, host immune defences try to 
eradicate the infection.  Pro-inflammatory mediators, such as Interleukin-8 (IL-
8)  and  IL-6,  expressed  by  respiratory  epithelium  recruit  and  activate 
inflammatory cells within the lungs.  Influx of polymorphonucleocytes (PMNs) 
produces a wide range of antimicrobial factors aimed at killing the bacteria. 
However, this can inadvertently lead to pulmonary deterioration and epithelial 
necrosis  (Fink  et  al,  2003).  Failure  to  clear  infection  causes  persistent 
neutrophil influx, leading to further damage to the lung. Overall, this indicates 
that successful treatment of CF requires in part halting the cycle of repetitive 
infections (Hassett et al, 2010).  
 
To summarise, pathogenic bacteria that infect the respiratory tract early in the 
course  of  CF  are  rarely  eradicated.  This,  coupled  with  an  aggressive 
inflammatory response, is thought to be a key player of irreversible airway 
damage  (Davies  et  al,  2009).    Failure  to  eradicate  these  organisms  are 
attributed to high-level multiple drug resistance, which is known to emerge Chapter 1: Introduction 
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during  treatment  (Poole,  2001),  and  may  be  associated  with  intrinsic 
resistance (biofilms) or induced resistance (efflux pump activity). Therefore, it 
is important to understand the microenvironment of the CF lung to gain further 
insight  into  how  successful  treatment  may  be  achieved.    However,  this  is 
difficult given the biofilm nature of microorganisms within the CF lung.  
 
1.2 CF an inflammatory disease if biofilm origin 
1.2.1 Introduction to biofilms 
Microbiologists  have  historically  studied  planktonic  (free  floating  and 
homogeneous)  cells  in  pure-culture.  However,  the  link  between  sessile 
(surface  attached  and  heterogeneous)  cells  with  microbial  pathogenesis  in 
human infection is now a mainstream ideology (TomLin et al, 2005).  Recent 
research reveals that a wide range of bacteria alternate between planktonic 
and sessile multicellular communities, commonly referred to as biofilms (Kvist 
et al, 2008). It is now estimated that up to 65% of microorganisms that cause 
human  infections  exist  in  biofilm  communities,  and  this  mode  of  growth  is 
considered the prevailing lifestyle of microorganisms (Smith et al, 2008).   
 
Biofilms  are  highly  structured  communities  within  a  3-dimensional 
architecture,  characterised  by  interstitial  voids,  water  channels  and 
microorganisms that are surface-associated, and/or attached to one another 
and encapsulated within a self-produced protective extracellular matrix (ECM) 
(Costerton et al, 2003) (Figures 1.1 and 1.2).  Microorganisms favour biofilm 
conditions as environmental stresses, such as nutrient deprivation, results in 
production  of  the  viscous  highly  pro-inflammatory  ECM  that  surrounds  the Chapter 1: Introduction 
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biofilm (Yoon et al, 2002; Worlitszch et al, 2002).  The ECM of P. aeruginosa 
is the result of a stress factor within the biofilm which promotes a mutation to 
over  produce  alginate,  thereby  offering  protection  from  host  immune 
responses and antimicrobial agents (Davies, 2002). 
 
 
Figure 1.1 Scanning electron microscopy (SEM) images depicting MRSA 
isolates forming weak (a), adherent (b) and significantly established (c) 
biofilms.  SEM  images  of  three  different  stages  of  biofilm  growth  and 
attachment are depicted. (a) initial attachment and development of a bacterial 
biofilm,  (b)  increasing  numbers  of  adhered  bacteria  are  evident  (c)  a  fully 
established microbial biofilm (Smith et al, 2008). 
 
Biofilms can develop on either biotic or inert substrates from a single species 
or as a community derived from several species. Thereby, biofilms can be 
considered  as  complex  cities  of  microbes  that  cooperatively  interact  in  an 
altruistic manner (Hoffman et al, 2005).  The advantages for microorganisms 
in  forming  a  biofilm  include  protection  from  the  environment,  resistance  to 
physical  and  chemical  removal  of  cells,  metabolic  cooperation  and  a 
community based regulation of gene expression (Tote et al, 2009). Table 1.1 
highlights the general features of biofilm infections in human host tissues.   
 Chapter 1: Introduction 
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Figure  1.2  SEM  images  depicting  clinically  important  oral  biofilms 
formed in vitro.  (a) Biofilm representative of subgingival periodontal plaque, 
consisting  of  Streptococcus  mitis  (Sm),  Fusobacterium  nucleatum  (Fn), 
Aggregatibacter actinomycetemcomitans (Aa) and Porphyromonas gingivalis 
(Pg). (b) Streptococcus mutans biofilm. Polymeric matrix material (arrow) is 
evident  surrounding  the  coccoid  cells.  (c)  Candida  albicans  biofilm. With  a 
combination  of  yeasts  (Y)  and  hyphae  (H)  that  form  a  lattice  network  to 
support the structure. The scale bar represents 10µm. (Ramage et al, 2010).Chapter 1: Introduction 
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Table  1.1    General  features  of  biofilm  infections  in  humans  compared  with  acute  planktonic  infections  and 
superficial colonisation/normal flora of skin and mucosal membranes (Adapted from Hoiby et al, 2010). 
Features of biofilm 
infections 
Necessary condition for 
biofilm infection 
Sufficient condition for 
biofilm infection 
Also found in acute 
planktonic infection 
Also found in 
colonisation/normal 
flora on skin and 
mucosal membranes 
Aggregates of bacteria 
embedded in a self-produced 
polymer matrix 
Yes  Yes  No  No / Yes 
Tolerant to innate and 
adaptive immune responses 
Yes  Yes  No  No / Yes 
Inflammation  Yes  No  Yes  No 
Biofilm-specific antigens  Seldom  Seldom  No  No 
Antibody response  Yes (after some weeks)  No  Yes (after some 
weeks) 
No 
Chronic infection  Yes  Yes  No  No 
Foreign-body associated 
infections 
No  Yes  No (yes on first day of 
infection) 
No 
Localised infections  Yes  No  Yes  Yes 
Focus for spreading or local 
exacerbation 
Yes  No  Yes  Yes Chapter 1: Introduction 
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1.2.2 Bacterial biofilms associated with CF 
Bacteria that persist in lungs of CF patients preferentially survive as a biofilm 
in order to improve their potential for survival (Tote et al, 2009).  The detection 
within  CF  sputum  of  quorum  sensing  molecules,  which  are  used  by  P. 
aeruginosa for cell-to-cell communication in vitro, provides evidence that P. 
aeruginosa form biofilms in the CF lung (Moreau-Marquis et al, 2008). Inhaled 
bacteria  in  planktonic  form  initially  attach  to  cell  surface  receptors  on 
respiratory  epithelial cells.  In  particular,  respiratory  cells  within  CF  patients 
have  an  abundance  of  asialoGM1  receptors  on  their  surface  that  P. 
aeruginosa  pili  and  flagella  attach  to  (Saiman  et  al,  2003).    The  CF  lung 
provides an environment that allows conversion of this microorganism from a 
motile planktonic form to a mucoid sessile biofilm mode of growth (Kirov et al, 
2007).  This conversion in mode of P. aeruginosa growth is important as the 
microorganism often loses its associated polar flagellum during chronic airway 
disease.    The  absence  of  this  structure  enables  the  bacterium  to  become 
undetectable to the host immune system. As a consequence the host fails to 
initiate  IL-8  production  in  response  to  the invading  microorganism,  thereby 
resulting  in  diminished  neutrophil  recruitment  (Hassett  et  al,  2010).  
Furthermore, the non-mucoid P. aeruginosa phenotype is considered to be 
harmLess  as  infections  with  this  phenotype  do  not  significantly  alter  lung 
function or antibody response (Pedersen et al, 1992).   
 
P.  aeruginosa  biofilms  within  the  CF  lung  live  in  stagnant  microaerophillic 
mucus.  It  is  understood  that  such  biofilms  favour  anaerobic  conditions, 
facilitating  microbial  growth  to  be  3-fold  greater  than  microbes  grown  in Chapter 1: Introduction 
 
9 
 
aerobic  conditions  (Yoon  et  al,  2002).    Biofilms  that  form  under  these 
conditions leads to depleted oxygen levels in the lungs and are referred to as 
a  chronic  type  II  biofilm.  Within  these  types  of  biofilm,  bacteria  are 
encapsulated within the thick and stagnant mucus lining the CF airway (Major 
et al, 2010).  Many of these biofilm processes are controlled via cell-to-cell 
communication.  Stenotrophomonas maltophilia is very often co-isolated with 
P.  aeruginosa  from  CF  patients.  Pompilio  et  al  (2010)  demonstrated  S. 
maltophilia  was  capable  of  adhering  to  and  invading  CF-derived  IB3-1 
cultured  bronchial  epithelial  cells.  Furthermore,  they  identified  that  S. 
maltophilia  has  the  ability  to  form  biofilms  on  either  polystyrene  or  IB3-1 
cultured  epithelial  cells.  They  also  elucidated  that  P.  aeruginosa  standard 
laboratory  and  genetic  reference  strain  PAO1  significantly  improves  S. 
maltophilia  adhesiveness,  indicating  a  potential  synergistic  relationship 
between these pathogens.  The presence of B. cepacia pathogenic biofilms in 
CF patients elicits a robust neutrophilic response, resulting in an exacerbated 
production of pro-inflammatory mediators, such as elastase, reactive oxygen 
and  reactive  nitrogen.    This  neutrophilic  response  causes  progressive 
deterioration of the airway epithelium and underlying tissue, which ultimately 
leads to the premature death of CF patients (Major et al, 2010).   
 
1.2.3 Quorum sensing within bacterial biofilms of the CF lung 
Key  pathogenic  factors,  including  virulence  and  resistance,  are  controlled 
within  the  CF  lung  via  microbial  communication.  Bjarnsholt  et  al  (2009) 
established  that  biofilm  cells  of  P.  aeruginosa  recognise  the  presence  of 
attracted  PMNs  and  respond  to  this  inflammatory  response  via  cell-to-cell Chapter 1: Introduction 
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contact  with  surrounding  bacteria  through  signalling  molecules.  These  are 
recognised  to  be  quorum  sensing  (QS)  molecules,  which  are  widespread 
among different bacterial genera, emphasising the importance of coordinating 
bacterial behaviour as a group (Horswill et al, 2006).  
 
QS regulation plays an important role in infections caused by opportunistic 
pathogens (Bjarnsholt et al, 2007).  QS molecules induce the expression of 
genes in bacteria that are vital to biofilm formation, these include, virulence 
genes, surface motility and controlling antimicrobial resistance genes within 
the CF biofilm (Davies, 2002; Taga et al, 2003; Zhu et al, 2002).  In bacterial 
communities  QS  systems  can  be  viewed  as  a  global  regulatory  system 
controlling the expression of numerous genes and phenotypes (Willcox et al, 
2008).  Bacteria can monitor population density via chemical communication 
allowing the bacteria to coordinate the behaviour of the group much like the 
characteristics  observed  in  multicellular  organisms  (Taga  et  al,  2003). 
Bacterial cells are not physically aware of the presence of other bacteria, but 
can  sense  the  concentration  of  signal  molecules  (Bjarnsholt  et  al,  2007). 
Sensing  is  achieved  via  the  production  of  small  signal  molecules  called 
autoinducers,  which  consist  of  3  components:  signal  molecules,  signal 
synthesis and signal receptors (Brackman et al, 2009). The acyl-homoserine 
lactone  (acyl-HSL)-based  signalling  systems  are  the  most  well  studied 
examples of QS with more than 70 Gram-negative bacterial species reported 
to  use  acyl-HSL  based  systems  (Taga  et  al,  2003).    Gram-positive  QS 
bacteria  usually  use  a  modified  oligopeptide  two-component  circuit  as 
communication signals (Zhu et al, 2002). Chapter 1: Introduction 
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Work  conducted  by  Riedel  et  al  (2002)  provided  evidence  that  both  P. 
aeruginosa and B. cepacia form mixed biofilms in the lungs of CF patients and 
are capable of communicating with each other utilising the QS acyl-HSL thus 
contributing to the infection process in diseased states within the host (Figure 
1.3).   
 
 
Figure 1.3 QS is accountable for virulence factors and diseased states in 
the CF lung. 
QS regulated virulence factors (in green) are important mediators in infections 
of the lung and account for diseased state.  Shown in red are the effects of 
QS  AHL  signal  on  the  host  response,  indicating  infiltration  of  PMNs  and 
macrophages  which  damage  host  tissue  by  release  of  reactive  oxygen 
species (Willcox et al, 2008). 
 
QS in P. aeruginosa  is well understood and is comprised of two acyl-AHL 
synthases,  LasI  and  RhlI,  that  generate  N-3-oxododecanoyl  homoserine 
lactone  (3O-C12)  and  N-butyryl-HSL  (C4-HSL),  respectively  (Wilder  et  al, 
2009).   As these signals accumulate exponentially within the community they 
bind to their cognate transcriptional regulators LasR and RhIR, respectively, 
activating  expression  of  target  genes  (Juhas  et  al,  2005)  Therefore,  P. Chapter 1: Introduction 
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aeruginosa virulence factors including secreted toxins are under the control of 
the  QS  regulatory  system  (Winstanley  et  al,  2008).  P.  aeruginosa  is 
dependent on the QS molecule 3O-C12 to drive expression of virulence genes 
which  in  turn  induce  pro-inflammatory  cytokines  such  as  IL-6  and  IL-8  in 
airway epithelial cells (Figure 1.4) (Mayer et al, 2011).   
 
 
Figure  1.4  P.  aeruginosa  QS  regulatory  system  is  associated  with 
virulence factors in the CF lung. 
P.  aeruginosa  QS  regulated  virulence  factors  and  their  relevance  to  CF, 
indicating the intrinsic links between the QS regulon and biofilm formation, 
cytokine  production,  inflammatory  factors,  impaired  lung  function  and 
recruitment of PMNs (Winstanley et al, 2008). 
 
In  conjunction  to  these  findings,  the  B.  cepacia  QS  system  cepIR  (a 
homologue of the lasIR/rhlIR system identified in P. aeruginosa) is known to 
control  expression  of  the  transcriptome  and  proteome  associated  with 
virulence  factors  and  biofilm  formation  (TomLin  et  al,  2005).    This  group Chapter 1: Introduction 
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demonstrated that B. cepacia cepI and cepR mutant biofilm biomasses were 
less than half of the observed value compared to the wild type strain K56-2. 
These findings indicate that both mutants were structurally impaired in both 
initial attachment stages and further biofilm development (TomLin et al, 2005). 
These investigations highlight the importance of QS in biofilm development 
and bacterial disease progression. 
 
1.2.4 Antimicrobial resistance in CF lung 
During chronic co-infection, P. aeruginosa and B. cepacia aggregate in mixed 
biofilms  in  the  lungs  of  CF  patients  and  synergistically  enhance  antibiotic 
resistance  and  persistent  infection  (Riedel et  al,  2002).    This  resistance  is 
attributed to the multicellular nature of biofilm communities, such as delayed 
penetration  of  the  antibiotic  into  the  biofilm,  slower  growth  rates  in  some 
biofilms  that  undermines  antibiotics  that  target  cell  growth,  and  altered 
microenvironments  that  antagonise  the  action  of  the  antibiotic  (Figure  1.5) 
(Kirov et al, 2007).   
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Figure 1.5  Resistance mechanism of a bacterial biofilm. 
Proposed-biofilm associated resistance mechanisms: (1) Antimicrobial agents 
may fail to penetrate beyond the surface layers of the biofilm. Outer layers of 
biofilm cells absorb damage. Antimicrobial agents action may be impaired in 
areas of waste accumulation or altered environment (pH, pCO2, pO2, etc). (2) 
Antimicrobial agents may be trapped and destroyed by enzymes in the biofilm 
matrix. (3) Altered growth rate inside the biofilm. Antimicrobial agents may not 
be  active  against  non-growing  microorganisms  (persister  cells).  (4) 
Expression  of  biofilm-specific  resistance  genes  (efflux  pumps).  (5)  Stress 
response to hostile environmental conditions (leading to an over-expression of 
antimicrobial agent-destroying enzymes) (Pozo and Patel, 2007). 
 
In the biofilm community, mutations also occur that prove advantageous for 
the survival of bacteria (Zarantonellie et al, 2005).  Alterations of drug targets 
or enzymatic inactivation of antimicrobial agents are well known mechanisms 
of  antimicrobial  drug  resistance.    Recently,  active  drug  efflux  has  become 
increasingly  important  in  understanding  multidrug  resistance  (Hasdemir, 
2007).  Genes which regulate the expression of multidrug-efflux pumps are 
frequently  mutated  in  P.  aeruginosa.    Indeed,  inactivation  of  the  negative 
regulator of the MexXY-OprM multidrug efflux pump increases resistance to 
aminoglycoside and other drugs (Feliziani et al, 2010).  Chapter 1: Introduction 
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Efflux pumps are responsible for the removal of intracellular toxic substances 
and  metabolites  in  addition  to  excretion  of  signalling  molecules  into  the 
environment  to  facilitate  cell-to-cell  communication  (Kriengkauykiat  et  al, 
2005).  Resistance  nodulation  cell  division  (RND)  type  multidrug  efflux 
proteins  function  with  an  outer  membrane  pore  and  a  membrane  fusion 
protein to pump out drugs. AcrAB-TolC of Escherichia coli, AcrAB homologue 
of  Salmonella  enterica  serovar  typhimurium,  MexXY-OprM,  MexC-MexD-
OprJ,  MexE-MexF-OprN,  and  MexX-MexY-OprM  of  P.  aeruginosa  and 
CeoAB-OpcM of B. cepacia are typical examples of such systems (Hasdemir, 
2007, Chan et al, 2003).  Table 1.2 summarises the structure and substrate 
activity of these efflux pumps. 
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Table  1.2  Structure  and  substrate  specificity  of  the  three-component 
active efflux system in P. aeruginosa (Adapted from Strateva et al, 2009,) 
Cytoplasmic 
Membrane 
Pump 
Periplasmic 
Linker 
Outer 
Membrane 
Channel 
Substrate 
MexB  MexA  OprM  Quinolones, 
Macrolides, 
Tetracyclines, 
Lincomycin, 
Chloramphenicol, 
Novobiocin, 
β-lactams. 
MexD  MexC  OprJ  Quinolones, 
Macrolides, 
Tetracyclines, 
Lincomycin, 
Chloramphenicol, 
Novobiocin, 
Penicillins. 
MexF  MexE  OprN  Fluroquinolones, 
Carbapenems 
MexY  MexX  OprM  Quinolones, 
Macrolides, 
Tetracyclines, 
Lincomycin, 
Chloramphenicol, 
Aminoglycosides, 
Penicillins. 
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In Gram-negative bacteria, most efflux pumps are three-component systems 
that span the inner and outer membranes and contain a periplasmic linker 
protein,  which  allows  the  other  two  components  to  come  into  contact  with 
each other (Lomovskaya et al, 2001) (Figure 1.6).   
 
 
Figure  1.6  Overview  of  P.  aeruginosa  efflux  mediated  resistance  to 
tetracycline based antibiotics.  
Mechanism  of  action  of  efflux  pumps  against  antibiotics.  Structure  and 
function  of  the  MexAB-OprM  and  related  efflux  pumps  of  P.  aeruginosa. 
Antibiotics  can  be  captured  from  the  periplasmic  space,  cytoplasmic 
membrane,  and/or  cytoplasmic  space  by  MexB,  D,  F,  or  Y  (RND  exporter 
proteins). MexA, C, E, or X (MFP proteins) serve as conduits between the 
cytoplasmic and outer membranes. OprM, J, or N serves as the final step in 
removal of the antibiotic from the cell  (Aeschlimann, 2003).   
 
The four multidrug  resistant  RND efflux  pumps of  P.  aeruginosa  all  confer 
various degrees of resistance to fluroquinolones  (Lomovskaya et al, 2001).  
Resistance  is  attributed  to  a  reduced  outer  membrane  permeability  of  B. 
cepacia, production of modifying enzymes and alteration of antibiotic targets 
(Guglierame et al, 2006).  However, information relating to the contribution 
that drug efflux systems play in the drug resistance of B. cepacia is limited. Chapter 1: Introduction 
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Only  a  few  multidrug  efflux  pumps  have  been  described  to  date  in  some 
clinical isolates (Buroni et al, 2009).  Investigations conducted by Wigfield et al 
(2002) discovered that the immuno-dominant antigens of B. cepacia are in 
part a multidrug efflux pump responsible for resistance to both nalidixic acid 
and tetracycline (Wigfield et al 2002). 
 
Dean et al (2003) elucidated that resistance of P. aeruginosa to tetracycline 
antibiotics is a result of specific tetracycline-specific efflux pumps that differ 
from  RND  pumps.    The  investigations  demonstrated  that  PAO1  laboratory 
strain exhibited reduced susceptibility to the tetracycline derivative tigecycline 
(Dean  et  al,  2003).    Action  of  these  efflux  pumps  were  capable  of  being 
blocked using efflux pump inhibitors (EPIs), which are compounds that bind 
with the specific substrate pocket and inhibits efflux pump activity (Marquez, 
2005). MC-207,110 is the first identified broad spectrum EPI that effectively 
inhibits all clinically relevant efflux pumps in Gram negative bacteria (Pages et 
al, 2005).  Specifically, the MexAB-OprM and MexCD-OprJ efflux pumps of P. 
aeruginosa  have  been  shown  to  be  involved  in  biofilm  mechanisms  for 
resistance to the macrolide azithromycin (Gillis et al, 2005).  Kvist et al (2005) 
demonstrated that E.coli, P. aeruginosa, S. aureus and Klebsiella pneumonia 
strains exposed to the EPIs thioridazine, 1-(1-naphthlmethyl)piperazine and 
Phe-Arg-β-naphthylamide,    used  independently  or  in  combination,  reduced 
biofilm  biomass  by  80%  and  99%  respectively.    Whilst  also  reporting  that 
these EPIs synergistically increased susceptibility to antibiotic treatments.   
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1.2.5 Summary 
A plethora of Gram-positive and Gram-negative biofilm forming bacteria can 
cause direct destruction to host tissue and stimulate host cells to activate a 
wide range of inflammatory responses (Madianos et al, 2005).  Production of 
cytokines and chemokines from damage of tissues attract inflammatory cells 
to the site of infection, which persists despite antibiotic treatments and innate 
and adaptive responses (Hoiby  et al, 2010).  It is important to understand 
these processes and what role inflammatory mediators play in the infection 
process.Chapter 1: Introduction 
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1.3 Inflammation and the involvement of inflammatory mediators  
1.3.1 Introduction to Inflammation 
The innate immune system is the first line of host defence during an infection.  
It plays a key role in the early recognition and activation of pro-inflammatory 
responses to invading pathogens (Mogensen, 2009).  This ancient system of 
microbial recognition activates host defences via germ-line encoded receptors 
that  recognise  structural  components  of  microorganisms  (Dempsey  et  al, 
2003).  These microbial structures are termed pathogen associated molecular 
patterns  (PAMPs)  and/or  microbe-associated  molecular  patterns  (MAMPs), 
which are recognised by the hosts pattern recognition receptors (PRR) (Akira 
et al, 2006).  Specifically the family of PRR includes Toll-like receptors (TLRs), 
bacterial lipopolysaccharide (LPS) acts as a PAMP for TLR4, the bacterial cell 
constituent  peptidoglycan  is recognised  by  TLR3  and  bacterial flagellum  is 
recognised by TLR5 (Cigana et al, 2009).  The TLRs that recognise these 
molecular patterns during infection instigate the host’s inflammatory response, 
including  the  production  of  key  inflammatory  cytokines  and  chemokines 
(Havashi  et  al,  2011).    Immune  reactions  of  the  innate  system  involve 
cytokine-dependent  resistance  to  infection  from  pathogens.  Production  of 
cytokines  such  as  tumour  necrosis  factor  (TNF),  interferons  (IFNs), 
interleukins and chemokines combined with major histocompatibility complex 
(MHC)  independent  killing  are  essential  to  combat  invading  pathogens 
(Olszewska, 2005). Inflammatory cytokines, produced by infected damaged 
tissue,  aid  in  recruitment  of  cells  of  the  innate  immune  system,  primarily 
macrophages and neutrophils (Esche et al, 2005).  Acute inflammation is the 
initial response of the body to harmful stimuli and is achieved by increased 
movement  of  plasma  and  leukocytes  from  blood  into  injured  tissues. Chapter 1: Introduction 
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Movement of cells is attributed to an influx of inflammatory cytokines which 
co-ordinate  the  acute  phase  of  inflammation  (Dempsey  et  al,  2003).    This 
involves  the  local  vascular  system,  the  immune  system  and  various  cells 
within  the  injured  tissue.    Activated  inflammatory  cells,  including, 
macrophages  and  neutrophils  produce  pro-inflammatory  mediators,  which 
stimulate the production of matrix metalloproteinase’s (MMPs) (Alpagot et al, 
2006).  Neutrophils release antimicrobial oxidants and proteases and dead 
neutrophils  release  DNA,  which  can  directly  damage  tissue  causing  an 
additional increase in pro-inflammatory cytokines (Hassett et al, 2010) (Figure 
1.7) 
 
Figure 1.7 An example of inflammatory mediators involved in bacterial 
tissue damage. 
Macrophages  and  neutrophils  are  attracted  to  the  site  of  infection  and 
eliminate the pathogen by releasing a substantial amount of toxic products, 
such as reactive oxygen species, cytokines and MMPs.  Finally, pathogens 
are phagocytosed and tissue repair is initialised (Vanlaere, et al, 2009). 
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It is widely agreed that resolution of inflammation is an active process rather 
than a passive decay of pro-inflammatory signals (Van Dyke, 2008).  Recent 
research (Schwab et al, 2007) has identified biochemical pathways that are 
activated  during  inflammation,  thus,  pointing  to  an  active  biochemical 
resolution (Bhatavadekar et al, 2009).  Resolvin E1 (RvE1) and protectin D1 
(PD1) are mediators produced during the resolution stages of inflammation 
and termed resolution agonists (Schwab et al, 2007). Schwab et al (2007) 
demonstrated that both compounds at low (nanograms) concentration had the 
ability  to  regulate  the  effects  of  leukocyte  infiltration  and  furthermore  to 
stimulate macrophage phagocytosis of apoptotic PMNs, therefore concluding 
that this active process of resolution promotes return of tissue homeostasis 
(Serhan et al, 2007). 
 
1.3.2 Inflammatory mediators 
1.3.2.1 Introduction 
Inflammation  is  a  well-characterised  immune  response  of  innate  immunity, 
which  is  an  integral  part  of  defence  to  reduce  infection  within  the  host.  
Inflammation  can  be  divided  into  three  phases:  an  acute  phase,  immune 
response and a chronic phase (Salvie et al, 2005). These three inflammatory 
phases are tightly regulated by specific chemokines and cytokines due to the 
risk  of  mass  tissue  damage  by  reactive  oxygen  species  produced  by 
inflammatory  cells.    The  importance  of  these  inflammatory  mediators  and 
inflammatory  cells  in  relation  to  the  chronic  inflammatory  process  will  be 
discussed. 
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1.3.2.2 Cytokines and chemokines 
Cytokines  and  chemokines  are  important  non-matrix  targets  of  the 
inflammatory response.  Chemokines are a family of chemotactic cytokines, 
which attract leukocyte populations through interaction with specific receptors 
expressed  on  host  cells  (Garlet  et  al,  2003a).    Chemokines  produced  by 
airway  epithelial  cells  have  an  important  role  in  the  regulation  of  key 
inflammatory processes within the lungs (Krakauer et al, 2002).  Modulation of 
chemokine function can occur through several mechanisms, for example up-
regulation or inactivation by tissue proteases, including MMPs (Tosi, 2005).      
 
Pro-inflammatory mediators such as IL-8 and IL-6, expressed by respiratory 
epithelium,  recruit  and  activate  inflammatory  cells  in  the  lungs.  IL-8  acts  a 
chemoattractant factor for PMNs and can been found in  gingival crevicular 
fluid  (GCF)  in  patients  with  periodontal  disease  (Garlet  et  al,  2003b).  
Endothelial  cells,  fibroblasts  and  pulmonary  epithelial  cells  are  inherently 
linked  with  neutrophil  mediated  influx  at  sites  of  infection  (Standiford  et  aI 
1990).  PMNs produce a wide range of antimicrobial factors that have the 
ability  in  some  cases  to  eradicate  bacteria,  however,  these  molecules  can 
inadvertently lead to pulmonary deterioration and epithelial necrosis (Fink et 
al, 2003).  Standiford et al (1990) demonstrated that LPS stimulated A549 
cells  posses  effector  activity  associated  with  the  inflammatory  process  via 
generation of IL-8.  Work conducted by Krakauer et al (2002) demonstrated 
synthesis and expression of IL-6 and IL-8 from the A549 epithelial cell line.  
Furthermore, the biological activity and efficacy of IL-8 is unregulated by 10-
fold  when  processed  MMP-9,  therefore  resulting  in  a  more  potent Chapter 1: Introduction 
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chemoattractant (Lint et al, 2007).  IL-6 is associated with many inflammatory 
disorders, in particular, within bone biology. IL-6 has been shown to mediate 
metabolic  bone  disease  promoting  osteoclast  formation  resulting  in  the 
degradation of bone structures as seen in patients with periodontal disease 
(Kirkwood et al, 2003, Vernillo et al, 1994).  A study conducted by Kirkwood et 
al  (2003)  demonstrated  that  an  analog  of  the  tigecycline  derivative 
doxycycline termed CMT-8 (chemically modified tetracycline-8) decreased IL-
6  mRNA  stability  in  a  dose  dependent  manner.    This  was  achieved  by 
inhibiting  IL-1  beta-induced  IL-6  expression  in  MC3T3-cell  line  at  the  post 
transcriptional level, which is inherently important in gene regulation (Patil et 
al, 2004).  Therefore, indicating a potential role of doxycycline to positively 
mediate metabolic bone diseases mediated by the cytokine IL-6.  Furthermore 
Cazalis  et  al  (2009)  also  demonstrated  the  potential  therapeutic  effects  of 
tetracycline,  doxycycline  and  CMT-3  on  the  production  of  pro-inflammatory 
mediators IL-1 beta, IL-6 and IL-8  in an ex vivo human whole blood assay 
stimulated with LPS derived from the periodontal pathogen P. gingivalis.  The 
observed effects of this study demonstrated that tetracycline, doxycycline and 
CMT-3 showed positive reductions of the level of all LPS induced cytokines.  
Therefore, reducing the key pro-inflammatory mediators associated with, in 
particular,  periodontal  disease,  but  encompassing  chronic  inflammatory 
disease. 
 
1.3.2.3 Matrix Metalloproteinase’s (MMPs) 
MMPs are a family of zinc-dependent endopeptidases capable of degrading 
many extracellular matrix proteins by catalysing the breakdown of proteins on Chapter 1: Introduction 
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the cell plasma membrane or within the extracellular matrix (Preshaw et al, 
2004a).  MMPs  are  involved  in  the  cleavage  of  cell  surface  receptors,  the 
release  of  apoptotic  ligands,  and  chemokine/cytokine  activation  and 
inactivation (Lint et al, 2007).  To demonstrate the clinical relevance of MMPs, 
MMP mutant mouse strains have been generated.  These have identified the 
importance of MMPs towards cell proliferation, differentiation, adhesion and 
inflammation (Le et al, 2007). 
 
Currently, there are a total of 25 MMPs that have been characterised (Lint et 
al, 2007).   The identification of new non-matrix MMP substrates involved in 
inflammation  highlights  the  diverse  role  of  MMPs.  These  enzymes  can 
enhance  leukocyte  invasion  and  regulate  inflammatory  activity  of  serine 
proteases, cytokines and chemokines.  These host-derived enzymes play an 
important role in degradation of the extracellular matrix (Emingil et al, 2006a).   
Both MMP-2 and MMP-9 have been found to favour anti- or pro-inflammatory 
action respectively (Le et al, 2007).  
 
MMPs  are  important  for  creating  cellular  environments  required  during 
development  and  morphogenesis.    Under  normal  physiological  conditions, 
activities of MMPs are precisely regulated at the transcriptional level (Visse et 
al,  2003).  However,  MMP  host-derived  enzymes  produced  by  cells  in 
response to microbial virulence factors, in particular MMP-2 and MMP-9, are 
known to be induced by bacterial LPS (Albert et al, 2003).  MMPs are crucial 
for a normal immune response and are involved in neutrophil influx following 
LPS exposure.  This forms part of the early phase of the host response to Chapter 1: Introduction 
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LPS.  However, extensive release of these proteinases leads to severe tissue 
damage (Vanlaere et al, 2009).  
 
During  periodontal  and  lung  inflammation,  MMPs  are  under  the  control  of 
several  regulatory  mechanisms.    Up-regulation  is  controlled  by  inducers 
termed  extracellular  matrix  metalloproteinase  inducer  (EMMPRIN). 
Conversely,  inhibition  is  governed  by  inhibitors  termed  tissue  inhibitors  of 
metalloproteinases  (TIMPs)  (Emingil  et  al,  2006a).    These  molecules  are 
synthesised and secreted by most connective tissue cells and macrophages 
(Guignabert et al, 2005).  
 
Current  evidence  in  the  literature  demonstrated  by  Wong  et  al  (2009) 
identified  lung  MMP-2,  7,  10,  12,  14,  TIMP-1  and  4  to  be  involved  in  the 
pathogenesis of chronic obstructive pulmonary disease (COPD) and asthma 
(Wong  et  al,  2009).    Increased  serum  expression  of  MMPs  are  directly 
associated with bacterial-induced lung inflammation and attributed to impaired 
lung function (Roderfeld et al, 2009).  Expression of MMP-1, 2, 3, 7, 8, 9, 12, 
13,  and  TIMP-1  have  been  characterised  in  sputum  and  bronchoalveolar 
lavage of patients with CF (Roderfeld et al, 2009). This evidence highlights the 
importance of these mediators in the inflammatory process and progression of 
diseased states within the host. 
 
There is increasing evidence that fragments of extracellular matrix proteins 
play an important role in inflammatory cell recruitment to the lung in animal 
models  of  airway  inflammation  (Gaggar  et  al,  2008).    Key  information  to Chapter 1: Introduction 
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understand activities of these proteins in different inflammatory airway disease 
could  aid  the  development  of  more  selective  therapeutics  for  diseases 
associated with inflammatory processes (Wong et al, 2009). 
 
1.3.2.4 Summary 
In summary, bacterial biofilms are primarily responsible for inflammation within 
host tissue. However, it is the inflammatory response to bacterial species that 
cause most damage  in  chronic inflammatory  disease.    A  well  orchestrated 
host  inflammatory  response  has  the  capability  to  eliminate  the  microbial 
challenge.    An  acute  inflammatory  response  that  is  resolved  in  a  timely 
manner  prevents  tissue  destruction.  However,  failure  to  return  tissue  to 
homeostasis  results  in  neutrophil  mediated  destruction  and  chronic 
inflammation (Van Dyke, 2007).  Chronic inflammation leads to a progressive 
shift in the type of cells present at the site of inflammation, characterised by 
simultaneous  destruction  and  healing  of  the  tissue  from  the  inflammatory 
process.   
 
 
  1.4 Tetracycline based antibiotics 
1.4.1 Introduction to tetracyclines 
Current research has identified that tetracycline related compounds can be 
beneficial  towards  the  treatment  of  several  chronic  inflammatory  diseases, 
including  periodontal  disease  and  cystic  fibrosis  (Raza  et  al,  2006).    The 
emergence  of  these  benefits  has  resulted  in  a  wider  understanding  of  the 
physiological,  cellular  and  molecular  mechanisms  of  the  inflammatory Chapter 1: Introduction 
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response, and how these responses may be better controlled and managed 
by  antibiotic  treatment  (Rempe  et  al,  2007).    These  studies  will  now  be 
discussed. 
 
Tetracycline  compounds  irreversibly  bind  to  the  30S  ribosomal  subunit 
through  an  interaction  with  16S  rRNA,  which  prevents  docking  of  amino-
acylated  tRNA.  Tetracyclines  were  discovered  in  the  1940s  by  Benjamin 
Duggar as a bioactive substance produced by the Gram positive bacterium 
Streptomyces (Zakeri et al, 2008) that exhibit activity against a wide range of 
microorganisms (Garrison et al, 2009).  Tetracyclines are inexpensive broad-
spectrum bacteriostatic antibiotics that have been used to treat a vast array of 
diseases caused by Gram-positive and Gram-negative organisms (Roberts, 
2003).  
 
Recent investigations have demonstrated tetracyclines to be effective in the 
treatment of a number of inflammatory diseases including periodontitis and a 
vast  array  of  central  nervous  system  pathologies  (Dunston  et  al,  2011).  
Tetracyclines  include  tetracycline,  chlortetracycline,  oxytetracycline, 
demeclocycline,  methacycline,  doxycycline,  minocycline,  and  tigecycline 
(Aminov  et  al,  2004).  Figure  1.8  highlights  the  chemical  structures  of  this 
diverse  group  of  antibiotics.    In  addition  to  their  antibacterial  activity, 
tetracyclines  have  a  number  of  non-antimicrobial  effects  shared  by  most 
tetracycline  compounds.  These  include  anti-oxidant,  anti-apoptotic,  anti-
metastatic and anti-inflammatory effects (Dunston et al, 2011). Chapter 1: Introduction 
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Figure 1.8 Chemical composition of the tetracycline class of antibiotics. 
Chemical structures of three different generations of tetracyclines: from the 
natural products  obtained from the  bacterium  Streptomyces  to  second  and 
third  generation  semi-synthetic  antibiotics  of  minocycline,  doxycycline  and 
tigecycline (Zakeri et al, 2008). 
 
 
1.4.2 Resistance to tetracyclines  
The  indiscriminate  use  of  this  class  of  drug  has  resulted  in  widespread 
resistance among many clinical isolates of bacteria. As a consequence, there 
has been a reduction in number of tetracycline-based antibiotics used to treat 
infections (Aminov et al, 2004).  Resistance to tetracycline based antibiotics is 
attributed  to  tetracycline  resistant  bacteria  that  carry  1  of  the  36  different Chapter 1: Introduction 
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required  tetracycline  resistant  genes  (tet  genes),  that  are  often  associated 
with  movable  elements  such  as  plasmids,  transposons,  conjugative 
transposons, and integrons (Roberts, 2003).  Thus, resistance to tetracycline 
antibiotics  can,  therefore,  be  transferred  to  human  pathogens  and 
opportunistic bacteria during infection via horizontal gene transfer.  
 
Lactobacillus sakei resistance to tetracyclines is attributed to two functional 
genes.    Ammor  et  al  (2008)  demonstrated  that  tetracycline  resistance  is 
conferred  via  a  transposon  associated  tet(M)  gene,  which  codes  for  a 
ribosomal protection protein and a plasmid carrying tet(L) gene coding for a 
tetracycline  efflux  pump.    Their  investigations  highlighted  that  tet  genes 
increased the MIC of tetracycline on from <32 mg/L to >256 mg/L  (Ammor et 
al  2008).    Plasmids  are  emerging  as  important  elements  for  resistance.  
Blanco  et  al  (2005)  described  three  separated  tet  genes  located  on  small 
plasmids  in  Actinobacillus  pleuropneumoniae  that  conferred  resistance  to 
tetracyclines,  a  tet(B)  gene  was  also  evident  to  confer  resistance  to 
tetracycline, doxycycline and minocycline (Blanco et al, 2005).   
 
Furthermore,  it  has  also  been  highlighted  that  mutations  to  bacterial  efflux 
pumps  can  result  in  resistance  to  tetracyclines  in  Neisseria  gonorrhoeae, 
Helicobacter  pylori  and  Mycobacterium  avium  (Roberts,  2003).    Work 
conducted by Zarantonelli et al (1999) demonstrated that a 4-fold increase in 
resistance to tetracycline resulting from of a one base pair deletion in the mtrR 
gene which codes for the bacteria mtrCDE efflux pump (Zarantonellie et al, Chapter 1: Introduction 
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2005).  To overcome these common resistance mechanisms, improvements 
of the classic chemical composition were designed and will be discussed. 
 
1.4.3 Second generation tetracyclines 
1.4.3.1 Doxycycline 
A  derivative  of  tetracycline  is  the  semi-synthetic  drug  doxycycline.  
Doxycycline was invented and clinically developed in the early 1960s by Pfizer 
Inc. and is marketed under the brand name Vibramycin (Chopra et al, 2001).  
Doxycycline exhibits broad-spectrum antibacterial activity that interferes with 
prokaryotic  protein  synthesis  at  the  ribosome  level  (Rempe  et  al,  2007).  
Doxycycline is commonly prescribed at 100 mg – 200 mg/day demonstrating 
bacteriostatic  effects  for  systemic  infections  (Golub  et  al  2001).    Multiple 
infectious  diseases  can  be  treated  with  doxycycline  including  brucellosis, 
pasteurellosis,  borreliosis,  rickettsioses,  trepanomatosis,  cholera, 
leptospirosis,  Q  fever,  pulmonary  and  urinary  infections  associated  with 
chlamydia and mycoplasma, gonococcia, and anthrax (Aupee et al, 2009).   
 
LaPlante  et  al  (2008)  demonstrated  the  pharmodynamic  abilities  of 
doxycycline in an in vitro murine model infected with methicillin resistant S. 
aureus  (MRSA).    Three  strains  of  MRSA  were  evaluated  that  displayed 
inducible macrolide lincosamide-streptogramin type B resistance (W2, R2507, 
R2529).  All three strains were susceptible to doxycycline with MICs of 0.25 / 
4 and 4 mg/L respectively, and also reduced biofilm biomass of respective 
strains over a 72 h time course (LaPlanet et al, 2008). Furthermore, El-Azizi 
(2007)  demonstrated  that  combination  therapy  of  doxycycline  with Chapter 1: Introduction 
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amphotericin B improved killing activity in vitro against Candida parapsilosis, 
C.  krusei  and  C.  glabrata  biofilms  by  18.94%,  24.52%  and  29.15%, 
respectively.   
 
However, bacterial resistance to antibiotics is common. The in vitro activity of 
minocycline and doxycycline were compared by Canton et al (2003) against 
epidemiologically  defined  CF  S.  maltophilia  isolates.    These  studies 
highlighted  that  doxycycline  was  less  active  against  these  strains  than 
minocycline with an MIC90 of 8 mg/L compared to minocyclines MIC90 of 1 
mg/L (Canton et al, 2003).  This resistance is due in part to the overuse of 
doxycycline to treat bacterial infections associated with CF.  
 
Doxycycline  exhibits  a  variety  of  additional  and  less  well-known  properties 
when used at sub-antimicrobial doses doxycycline (SDD).  Among these are 
separate and distinct anti-inflammatory properties that can be used to treat a 
range of inflammatory diseases associated with an influx of monocytes (Raza 
et al, 2006).  The effects of doxycycline at doses below clinical prescription 
concentrations  will  be  discussed  to  evaluate  what  role  they  may  play  in 
inflammatory disease caused by pathogenic bacteria.   
 
1.4.3.2  Current  in  vitro  research  of  subantimicrobial  doses  of 
doxycycline 
1.4.3.2.1 Introduction 
Golub et al (1983) initially reported the secondary beneficial properties of the 
tetracycline  compound,  minocycline,  independent  of  its  antimicrobial Chapter 1: Introduction 
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properties (Golub et al, 1983).  These initial findings were followed up, where 
it was demonstrated that a reduction in GCF collegenase activity was directly 
related to the sub-antimicrobial dose of oral administered minocycline given at 
40 mg, significantly below the 200 mg dose commonly prescribed (Golub et al, 
1985).  Golub termed this new emerging concept of managing periodontitis as 
host modulation therapy.  Current literature describes the use of SDD (20 mg 
Periostat®)  in  the  treatment  of  inflammatory  disorders  associated  with 
periodontal diseases (Choi et al, 2004; Golub et al, 2001; Emingil et al, 2004; 
Preshaw et al, 2004a; Thomas et al, 1998).  These current works, although 
not  exhaustive,  will  be  discussed  to  highlight  the  significant  importance  of 
these secondary benefits. 
 
1.4.3.2.2 Current research 
Caton et al (2001) demonstrated that an oral dose of SDD given twice daily in 
combination  with  scaling  and  root  planning  (SRP)  over  a  6  month  period 
resulted in clinical improvement of chronic periodontitis patients, and did not 
result in antimicrobial resistance to the compound.  Work conducted in 2001 
by Golub et al identified that patients receiving SDD twice daily for 12 weeks 
had  a  significant  reduction  in  the  destructive  actions  of  collagenases 
commonly  found  in  GCF  of  patients  with  chronic  periodontitis.    These 
investigations  also  demonstrated  that  the  oral  pathogens  Actinomyces  and 
Fusobacterium spp detected in subgingival plaque samples did not develop 
resistance to doxycycline and all isolates remained susceptible to 3 mg/L dose 
of doxycycline (Golub et al 2001).  
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Emingil et al (2004) demonstrated that SDD combined with periodontal SRP 
can reduce MMP-8 levels to 50% lower than placebo group patients suffering 
from  periodontal  disease  and  only  receiving  SRP  over  a  6  month  period.  
Similar findings were also demonstrated by Choi et al (2004), identifying that 
SDD in conjunction with a SRP program led to reduction in MMP-8, MMP-9 
and IL-6 synergistically over 120 days when compared to a placebo control 
group.  This  resulted  in  lower  levels  of  inflammation  at  sites  of  previous 
disease (Choi et al, 2004).  Preshaw et al (2004b) also demonstrated that 
SDD  was  of  clinical  benefit  in  the  treatment  of  chronic  periodontitis  by 
enhancing the efficacy of SRP.  The overall outcome of these and associated 
findings has resulted in the SDD at 20mg (Periostat®) being approved by the 
United  States  Food  and  Drug  Administration  (FDA)  as  an  effective  host 
modulatory drug for the treatment of periodontitis (Caton and Ryan 2011). 
 
Raza et al (2005) investigated the use of SDD and demonstrated a significant 
reduction in the key inflammatory cytokine, monocyte chemoattractant protein-
1 (MCP-1) in human lung epithelial cells.  Thus, indicating a potential role for 
SDD as a new anti-inflammatory therapeutic option for individuals with chronic 
lung disease.  Gu et al (2009) demonstrated doxycycline concentrations of  
0.1,  1  and  10µM  reduced  inflammatory  mediators  associated  with  chronic 
inflammation.  The group reported that doxycycline concentrations of 0.1, 1 
and 10µM reduced tumour necrosis factor-a (TNF-α) and MMP-9 levels by 
46%,  52%  and  71%,  and  18%,  20%  and  41%,  respectively.  Moreover, 
Guignabert  et  al  (2005),  showed  that  pre-treatment  with  doxycycline 
suppressed  production  of  MMP-9  by  infiltrating  macrophages,  and  also Chapter 1: Introduction 
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partially  inhibited  recruitment  of  inflammatory  cells  at  the  site  of  tissue 
damage,  thereby  almost  normalising  tissue  histology  of  inflamed  trachea.  
These findings were echoed by Lee et al (2004), who established that SDD 
was effective at reducing airway inflammation, airway hyper-responsiveness, 
and expression of MMP-9 mRNA and protein in a murine model of asthma. 
 
1.4.3.2.3 Summary 
In addition to its potent antibacterial effects, doxycycline possesses significant 
immunomodulatory  properties  that has  important effects  upon  inflammatory 
mediators  associated  with  oral  and  pulmonary  inflammation.    However, 
bacterial  resistance  to  tetracyclines  is  well  established.  Therefore, 
developments of the tetracycline antibiotics have led to new classes that are 
capable of overcoming bacterial resistance mechanisms.  This new class will 
now be discussed. 
 
1.4.4 Third generation tetracyclines 
1.4.4.1 Glycylcycline 
The  use  of  tetracyclines  has  been  limited  in  recent  years  because  of  the 
emergence  of  resistant  microorganisms  that  are  capable  of  efflux  and 
ribosomal protection mechanisms (Zhanel, et al 2004).  Such microorganisms 
include  P.  aeruginosa,  B.  cepacia,  E.coli  and  Salmonella  enterica  serovar 
typhimurium (Chan et al, 2007; Hasdemir, 2007; Feliziani et al, 2010; Wigfield 
et al, 2002).  To overcome this growing concern, there has been an expansion 
of antibiotic derivatives by synthetic improvements producing analogues that 
overcome current resistance mechanisms (Magalhaes da silva et al, 2010).  Chapter 1: Introduction 
 
36 
 
Such developments led to the discovery in  1993 of the third generation of 
tetracycline  antibiotics  called  glycylcyclines  (Pankey,  2005).    Glycylcyclines 
are  currently  the  only  derivative  that  exhibit  broad  antibacterial  activity 
comparable to early tetracyclines. They demonstrate potent activity against 
both Gram-positive and -negative bacteria, including strains that carry efflux 
and ribosome protection (Sum et al, 1998). 
 
1.4.4.2 Tigecycline 
The most developed glycylcycline to date is 9-tert-butyl-glycylamido derivative 
tigecycline  (Zhanel,  et  al  2004).    Tigecycline  (Tygacil)  is  a  glycylcycline 
containing semi-synthetic derivatives of minocycline, exhibiting an expanded 
broad  spectrum  of  in  vitro  activity  (Peterson  2008a).  Furthermore,  it  is  an 
effective treatment for community-acquired pneumonia, intra-abdominal, skin 
and  skin  structure  infections  (Rubino  et  al,  2010).  Glycylcyclines  were 
specifically  designed  to  overcome  tetracycline  resistance  mediated  by 
ribosomal protection proteins and tetracycline-specific efflux pumps (Olson et 
al, 2006).  This is achieved by tigecycline, which binds reversibly to a helical 
region (H34) on the 30S subunit of the bacterial ribosome, thereby blocking 
entry of aminoacyl transfer RNA into the A binding site of the ribosome (Figure 
1.9)   (Doan et al, 2006).    
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Figure  1.9  Action  of  tigecycline  within  the  bacterial  ribosome. 
Schematically  depicts  the  interaction  of  a  tigecycline  (Tygacil)  molecule 
interrupting  the  growing  chain  of  amino  acids  required  for  bacterial  cell 
function (www.tygacil.co.uk) 
Subsequently,  this  process  inhibits  protein  synthesis  by  preventing 
incorporation of amino acid residues into the elongated peptide chain.  This 
action is the result of the addition of a modified glycylamido moiety to the ninth 
position  of  the  D  ring  (Figure  1.10)  aiding  in  both  efflux  and  ribosomal 
resistance  (Peterson,  2008).    Work  conducted  by  Olson  et  al  (2006) 
demonstrated inhibition of protein synthesis with an in vitro translation assay. 
This determined the nature of the interaction of tigecycline with the A site of 
the  16S  rRNA  of  the  ribosome.    These  experiments  demonstrated  that 
tigecycline inhibits protein synthesis in an in vitro assay system, binding to the 
ribosome  5-fold  and  >100-fold  greater  affinity  than  minocycline  and 
tetracycline, respectively (Olson et al, 2006). 
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Figure  1.10  Comparison  between  the  chemical  composition  of 
minocycline and tigecycline. The chemical structure of minocycline and its 
derivative tigecycline.  The modification of minocycline is clearly seen by the 
addition of the bulky 9-tert-butyl-glycylamido side chain at position 9 on the D 
ring.  This  addition  provides  tigecycline  with  expanded  microbiological  and 
therapeutic benefits (Peterson, 2008). 
 
The  therapeutic  benefits  of  tigecycline  have  been  demonstrated  in  vivo  by 
Murphy  et  al  (2000)  where  cardiac  titers  of  vancomycin-susceptible 
Enterococcus  faecalis  were  reduced  in  a  rat  model  of  experimental 
endocarditis.    Tigecycline  is also  known  to  be  more  active  in  vitro  against 
MRSA and vancomycin-susceptible and resistant E. faecalis (Murphy et al, 
2000).  The  wide  ranging  effects  of  tigecycline  also  include  potent  activity 
against methicillin susceptible S. aureus (MSSA), methicillin susceptible and 
resistant  S.  epidermidis,  penicillin  susceptible  and  resistant  Streptococcus 
pneumoniae (Petersen et al, 2002; Pankey, 2005; Vouillamoz  et al, 2008).  Chapter 1: Introduction 
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These findings were mirrored in part by Petersen et al (2002), demonstrating 
that tigecycline was three times more effective than vancomycin in an in vivo 
model of MRSA infection.  
 
In relation to bacterial biofilm forming pathogens commonly associated with 
pulmonary diseases, tigecycline offers improved activity to many current CF 
therapeutic  agents.    Burkholderia  spp  display  varying  MIC  values  to 
tigecycline owing to the action of drug efflux systems, MIC50 and MIC90 values 
of 0.5 - 4 and 4 - 32 mg/L (Livermore et al 2008). These MIC values are lower 
than  those  compared  to  minocycline.    Tigecycline  appears  to  be  more 
efficacious against S. maltophilia with MIC50 and MIC90 of 0.5 - 1 and 2 mg/L 
respectively and an MIC range of 0.06 - 4 mg/L (Livermore et al 2008).  P. 
aeruginosa exhibits high levels of resistance to tigecycline with an MIC50 and 
MIC90 of 8 and ≥32, respectively, which is lower than minocycline MIC50 and 
MIC90 of ≥32 (Garrison et al, 2009).  Tigecycline has potent activity against 
Gram-positive  organisms,  demonstrating  an  MIC50  and  MIC90  for  MSSA  of 
0.12 and 0.25 mg/L, MRSA isolates have a slightly higher MIC50 and MIC90 of 
0.12 and 0.5 mg/L  (Norskov-Lauritsen et al, 2009). 
 
Smith  et  al  (2009a)  demonstrated  the  bacteriostatic  activity  of  tigecycline 
against MRSA biofilm isolates recording a MIC of 0.06 mg/L, however, 45% of 
biofilm  associated  bacterial  cells  survived  after  treatment  with  tigecycline.  
Earlier  findings  by  the  group  demonstrated  that  a  subinhibitory  dose  of 
tigecycline  (0.24  mg/L)  significantly  altered  expression  (18.6%)  of  biofilm 
forming MRSA genome  Smith et al (2008).  A plethora of genes encoding Chapter 1: Introduction 
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ribosomal proteins and virulence factors were upregulated. However, genes 
encoding biofilm-associated proteins, capsule synthesis enzymes and genes 
encoding toxic shock syndrome toxin 1 were significantly reduced (Smith et al 
2009b).    It  was  concluded  that  at  low  doses  tigecycline  may  promote 
advantageous  benefits  to  modulate  virulence  factors  associated  with  S 
.aureus.  These data are of significant importance as biofilm structures are 
difficult to eradicate and can display susceptibilities towards antimicrobials 10 
– 1000 times less than planktonic cells (Smith et al 2008).   
 
Furthermore, minocycline and doxycycline exert biological effects independent 
of  their  antimicrobial  activity,  which  include  inhibition  of  pro-inflammatory 
mediators and prevention of pathological tissue destruction (Amin et al, 1996). 
Doxycycline and tigecycline share commonality of their therapeutic uses and 
both  are  inhibitors  of  MMPs  (Skulason  et  al,  2009).  In  a  murine  model, 
Salvatore  et  al  (2009)  demonstrated  that  six  days  of  tigecycline  treatment 
significantly reduced lung inflammation, pulmonary pro-inflammatory cytokines 
and chemokines.  It was reported that tigecycline at 0.2 mg in 0.2 mL per 
mouse on the first day of treatment followed by 0.1 mg in 0.2 mL per mouse 
for a further 5 days reduced bronchoalveloar lavage Mycoplasma pneumonia 
cultures from 6 Log10 CFU/mL to approximately 4.5 Log10 CFU/mL.   This 
was coupled with a significant reduction of Interleukin-1β (IL-1β), Interleukin-
12 (IL-12) and Interferon gamma (IFN-y) (Salvatore et al, 2009).  The in vitro 
modulatory effect of tigecycline was also investigated by Saliba et al (2009), 
here  tigecycline  exhibited  anti-inflammatory  properties  independent  of  its 
antimicrobial effects. Tigecycline at subinhibitory concentrations demonstrated Chapter 1: Introduction 
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a reduction of TNF-α, IL-1β and IL-6 derived from staphylococcal enterotoxin 
B (SEB) and staphylococcal toxic shock syndrome toxin-1 stimulated human 
peripheral  blood  mononuclear  cells  (Saliba  et  aI,  2009).  These  findings 
provide evidence that subinhibitory concentrations of tigecycline can modulate 
the  inflammatory  process  through  its  inhibitory  effects  on  pro-inflammatory 
cytokines.   
 
Of  interest,  these  properties  of  immunomodulation  are  evident  in  other 
antibiotic compounds.  It is  well known that subinhibitory concentrations of 
antibiotics  may  be  beneficial  for  bacterial  communities,  by  facilitating 
increased  expression  of  virulence  genes  and  enhancing  biofilm  formation 
(Davies  et  al,  2006).  These  advantageous  properties  to  bacterial  biofilm 
formation were demonstrated by Hoffman et al (2005). They demonstrated 
that a subinhibitory concentration of aminoglycoside antibiotic induced biofilm 
formation  by  P.  aeruginosa  and  E.  coli  thereby  conferring  biofilm-specific 
aminoglycoside  resistance.    Nevertheless,  subinhibitory  concentrations  are 
also  capable  of  decreasing  virulence  factors  of  bacterial  communities  and 
immunomodulate  inflammatory  responses  (Ryan  et  al,  2008).    Indeed,  the 
semi-synthetic  macrolide  azithromycin  at  subinhibitory  concentrations 
decreases  biofilm  formation  of  highly  resistant  clinical  nontypeable 
Haemophilus  influenzae  (NTHi)  isolates  commonly  associated  with  early 
airway infections in CF (Starner et al, 2008).   
 
 
 Chapter 1: Introduction 
 
42 
 
1.4.4.3 Summary 
Current antibiotics produced by a range of microorganisms, in particular the 
actinomycetes and fungi, are now fast becoming outdated and less effective 
(Pelaez, 2006).  To overcome this problem, new antibiotic classes have been 
developed by chemical adaptations of original natural products. Research and 
development  of  antibiotics  has  led  to  the  production  of  semi-synthetic 
compounds  and  truly  synthetic  antibiotics.    These  classes,  specifically  the 
tetracyclines,  have  demonstrated  in  some  instances  secondary  beneficial 
characteristics.    Such  benefits  encompass  inhibition  of  extracellular  matrix 
degradation,  reduced  inflammatory  pulmonary  cytokines  and  chemokines 
associated  with  chronic  inflammatory  lung  disease  and  advantageously 
modulating  pro-inflammatory  cytokines  and  MMPs  associated  with  chronic 
periodontitis  (Gu, et al 2009, Salvatore et al, 2009 and Choi et al, 2004).  It is 
apparent that tetracyclines, such as tigecycline, may play a dual role both in 
terms of their antibacterial activity and in relation to modulating deleterious 
immune responses.   
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1.5 General overview 
Bacterial pathogens that utilise multidrug resistant efflux pumps, as part of 
antibiotic resistance, are of key importance to bacterial disease progression 
and will be investigated.  These investigations will examine the role of efflux 
pumps in planktonic and sessile bacterial cells and incorporate a competitive 
efflux pump inhibitor to determine susceptibility to tigecycline.  The results of 
these  investigations  may  provide  insight  to  present  new  opportunities  to 
effectively treat bacterial related infections. 
 
Currently,  there  is  limited  information  within  the  literature  surrounding  the 
beneficial effects of tigecycline on inflammatory mediators. In particular, the 
effects  of  tigecycline  upon  IL-6,  IL-8  and  specific  MMPs  produced  during 
chronic inflammation by immune cells and host tissue is not well established. 
It  is  of  current  interest  to  investigate  if  subinhibitory  concentrations  of 
tigecycline could beneficially modulate the production of IL-6, IL-8 and MMPs 
derived  from  clinically  relevant  human  cell  lines.    Thus,  determining  if 
tigecycline could mirror current in vitro research associated with SDD. 
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1.6 Aims of the study  
The  aim  of  this  study  was  two-fold:  Initially  investigate  the  efficacy  of 
tigecycline against important Gram-negative CF and periodontal pathogens, 
and to examine if clinically relevant cell lines exposed to tigecycline possess 
any immunomodulatory properties. 
 
The study will therefore investigate the following: 
1.  Microbiological capacity of tigecycline 
To examine the effects of tigecycline on inhibition and killing of planktonic and 
sessile bacteria associated with CF and periodontitis.  Examine the role of 
efflux  pumps  associated  with  antibiotic  resistance  using  tigecycline.  
Incorporate efflux pump inhibitors to determine if efflux pumps are employed 
during infection. 
  1a) Anti-biofilm activity 
1b) Role of efflux pumps in CF and periodontal pathogens 
 
2. Immunomodulatory capacity of tigecycline 
Examine the immunomodulatory capacity of subantimicrobial concentrations 
of tigecycline using clinically relevant cell lines by: 
2a)  The Investigation of the effects of subantimicrobial doses of tigecycline on 
IL-6  and  IL-8  production  from  pulmonary  derived  A549  and  oral  derived 
OKF6/TERT2 cell lines.  
2b) The Investigation of the effects of these concentrations on neutrophil 
derived IL-8 and MMP-9 release. Chapter 2: Material & Methods 
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2    Material and methods 
2.1  Antimicrobial properties of tigecycline 
 
2.1.1   Preparation of tigecycline and storage 
Tigecycline  white  powder  was  kindly  gifted  by  Wyeth  Pharmaceuticals 
(Princeton, New Jersey, USA) and used in all antimicrobial and immunological 
experiments. Tigecycline was prepared by adding 10 mg of powder into 10mL 
of sterile doubled distilled water (ddH2O [Oxoid, UK]) and sterilized using a 
0.22µL filter (Millipore, UK). This 1 mg/mL solution was stored at -80
oC, and a 
new  stock  solution  prepared  on  a  weekly  basis.  Tigecycline  was  used  at 
varying concentrations dependent upon each experimental parameter. 
 
2.1.2  Bacterial strains and maintenance 
The bacterial strains used throughout these experiments were comprised of 
both oral and pulmonary pathogens. The Burkholderia strains were isolated 
from  children  with  cystic  fibrosis  at  the  Royal  Hospital  for  Sick  Children 
(Yorkhill  Division),  Glasgow,  UK  (courtesy  of  Dr  Craig  Williams)  and  from 
Foothills Hospital, Calgary, Canada (courtesy of Dr Douglas Storey) (Table 
2.1).  The  oral  bacteria  used  in  these  experiments  are  all  associated  with 
chronic inflammatory diseases of the periodontium (Porphyromonas gingivalis, 
Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans) were 
obtained from culture collections within Glasgow Dental Hospital, Glasgow UK 
(courtesy of Prof Andrew Smith) (Table 2.2). All strains were stored routinely 
in Microbead tubes (Prolab diagnostics, UK) at -80
oC until required.   
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Pulmonary  clinical  isolates  were  maintained  and  incubated  at  37
oC 
(Laboratory  Thermal  Equipment,  UK)  in  either  Luria  broth  (LB)  (Sigma, 
Aldrich, UK) or LB agar.  Cation supplemented Mueller Hinton Broth (MHB) 
(Fluka, UK) was used throughout all susceptibility testing assays.  For the oral 
clinical isolates, A. actinomycetemcomitans were maintained and grown in 5% 
CO2  (Binder,  USA)  at  37
oC  in  tryptic  soy  broth  (TSB)  (Oxoid,  UK) 
supplemented  with  0.8%  glucose  (Fisher  Scientific,  UK)  and  0.6%  yeast 
extract  (Oxoid,  UK).  TSB  was  used  throughout  all  susceptibility  testing 
assays.  P. gingivalis and F. nucleatum spp were maintained and grown in an 
anaerobic chamber (85% N2, 10% CO2, 5% H2, Don Whitley Scientific, MK3 
anaerobic work station, Bradford, UK) on blood agar at 37
oC.  Blood agar was 
prepared on site using Columbia media (Oxoid, UK) supplemented with 5% 
v/v  lysed  horse  blood  (E&O  Laboratories  Limited,  Scotland)  and  1.5%  w/v 
bacteriological agar (Bioconnections, UK).  Schadlers anaerobic media (SAM) 
(Oxoid, UK) was used throughout all susceptibility testing assays. 
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Table  2.1  Pulmonary  strains.    Burkholderia  spp  used  in  the  following 
experiments comprised 17 strains of Burkholderia cepacia complex: 9 strains 
from  Yorkhill  (YK),  6  from  Calgary  (CG)  and  two  type  strains  (K56-2  and 
American  Type  Culture  Collection  ATCC  117765).  Three  strains  of 
Burkholderia gladioli were obtained from Yorkhill. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Burkholderia cepacia complex 
(genomovar) 
Burkholderia gladioli 
YH06.79061A (II)  YH07.14759A 
YH06.70610 (II)  YH08.56940A 
YH08.29412A(II)  YH09.6793 
YH07.24721A (II) 
K 56-2 (III) 
CG13862-1 (III) 
ATCC 117765 (III) 
YH07.37324A (III) 
YH08.32475A (III) 
CG16192 (III) 
CGJ415 (III) 
CGJ2315 (III) 
CG1394 (III) 
CG6433 (III) 
YH05.56937A (IV) 
YH07.24721B (V) 
YH07.59399B (V) Chapter 2: Material & Methods 
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Table 2.2  Oral  strains.    The  oral  isolates  used  in  the  following 
experiments  comprised  of  5  strains  of  P.  gingivalis,  including  1  national 
collection of type cultures (NCTC) strain; 4 F. nucleatum, including 1 NCTC 
strain; and 3 strains A. actinomycetemcomitans, including 2 NCTC strains.  All 
strains were obtained from Glasgow Dental Hospital culture collection. 
   
Porphyromonas gingivalis 
W50 
2111 
2114 
2098 
11834 (NCTC) 
Fusobacterium nucleatum 
494 
10562  (NCTC) 
01/105 (1) 
01/105 (3) 
Aggregatibacter actinomycetemcomitans 
10981 (NCTC) 
10982  (NCTC) 
9707 
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2.1.3  Sensitivity testing of tigecycline 
2.1.3.1 Standardisation of bacterial inoculum  
Pulmonary isolates and controls (K-56-2 and ATCC 117765) were grown in 
10mL of LB media in an orbital shaker (IKA®, KS4000i control, Germany) at 
37
oC overnight. Cells were then centrifuged, washed with sterile phosphate 
buffered saline (PBS) and resuspended in 10 mL sterile PBS.  Oral isolates 
and controls (11835 NCTC, 10562 NCTC and 10981 NCTC) were grown on 
either  blood  agar  plates  (A.  actinomycetemcomitans)  or  on  fastidious 
anaerobic  agar  (Oxoid,  UK)  (P.  gingivalis  and  F.  nucleatum)  for  48  h  in 
anaerobic incubator at 37
oC and in 5% CO2, respectively.  A loopful of each 
strain  was  placed  in  10mL  of  respective  media  and  placed  back  in  the 
anaerobic  chamber  at  5%  CO2  at  37
oC  for  a  further  48  h.  Cells  were 
standardised to an optical density at 550nm (OD550nm) of 0.20 (equivalent to 1 
x  10
8  CFU/mL)  using  a  spectrophotometer  (Fisher  Scientific,  Colorimeter 
model 45, USA). Cells were subsequently diluted 1:100 in 10mL of respective 
media to provide approximately 1 x 10
6 cells per mL, which was then used for 
sensitivity testing. 
 
2.1.3.2 Efflux Pump Inhibitor preparation and maintenance 
EPI L-Phe-L-Arg-ß-naphthylamide (MC-207,110) (Sigma, UK) was used for all 
susceptibility testing at a concentration of 64 mg/L in each experiment.  EPI 
was  prepared  by  adding  10  mg  of  MC-207,110  powder  to  10mL  of  sterile 
ddH2O, which was subsequently sterilised through a 0.22µL filter.   
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2.1.3.3 Sensitivity testing of oral and pulmonary planktonic bacteria to 
tigecycline ± EPI 
Cells  were  standardised  as  described  in  Section  2.1.3.1.  The  MIC  of 
tigecycline  was  determined  by  standard  Clinical  and  Laboratory  Standard 
Institute  (CLSI)  broth  microdilution  methodology  in  96-well  round  bottom 
plates (Costar, UK).  This technique was employed to highlight the effect of 
different concentrations of MC-207,110 on the MIC of tigecycline.  Tigecycline 
was tested at a range from 0 to 128 mg/L alone and in combination with MC-
207,110.   Burkholderia isolates were exposed to serial doubling dilutions of 
tigecycline ± MC-207,110 at 64 mg/L sealed with parafilm (Pechiney, plastic 
packaging,  USA)  and  incubated  for  24  h  at  37
oC.    P.  gingivalis  and  F. 
nucleatum spp was incubated for 48 h in an anaerobic chamber at 37
oC.  The 
methodology was identical for the A. actinomycetemcomitans spp, however 
plates were placed in an aerobic incubator with 5% CO2 at 37
oC for 48 h.  The 
MICs were determined based upon inhibition of growth when visualised by 
looking at the bottom of the plate with the naked eye. 
 
2.1.3.4  Sensitivity  testing  of  oral  and  pulmonary  sessile  bacteria  to 
tigecycline ± EPI 
Burkholderia  spp  isolates  were  prepared and  standardised  as  described  in 
Section 2.1.3.1.  Biofilm formation was based on methodology adapted from 
Ceri, et al (1999).  Two hundred microlitres of standardised bacterial cells was 
added to wells of a 96-well NUC peg plate (NUC, Denmark) with column 12 
serving as the negative control with MHB media only.  Inoculated plates were Chapter 2: Material & Methods 
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sealed with parafilm and placed in an incubator on a rocking platform (Grant 
bio, UK) at 37
oC for 72 h to allow culture media to wash over the pegs and 
form  a  mature  biofilm.    After  72  h,  adhered  biofilms  were  visible  on  pegs 
inserted into the culture media.  
 
P.  gingivalis,  F.  nucleatum  and  A.  actinomycetemcomitans  isolates  were 
prepared  and  standardised  as  described  in  Section  2.1.3.1.    Two  hundred 
microlitres of standardised bacterial cells were added to each well of a 96 well 
flat  bottom  plate  (Costar)  with  column  12  serving  as  the  negative  control 
containing  TSB  media  only  for  A.  actinomycetemcomitans  and  Schadlers 
media only for P. gingivalis and F. nucleatum.  Inoculated plates were sealed 
with parafilm and placed in an anaerobic chamber at 37
oC for 48 h to allow a 
mature biofilm to form on the bottom of the plate.  After 48 h, adhered biofilms 
were  visible on the base of each well and washed gently with  sterile PBS 
before  each  experiment.    The  methodology  was  identical  for  the  A. 
actinomycetemcomitans  spp,  however  they  were  grown  in  an  aerobic 
incubator with 5% CO2 at 37
oC for 48 h. 
 
Susceptibility of Burkholderia spp to tigecycline ± EPI was assayed using a 96 
peg plate and a 96-well flat bottom plate (NUC, UK).  B. cepacia species (spp) 
was exposed to serial doubling dilutions of tigecycline ± MC-207,110 at 64 
mg/L sealed with parafilm and incubated at 37
oC atmosphere for 24 h.  After 
inoculation, plates were incubated at 37
oC atmosphere for 24 h.  The MICs 
were determined based upon inhibition of growth when visualised by looking 
at  the  relative  biomass  on  each  peg.    Subsequent  biomass  and  viability Chapter 2: Material & Methods 
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assays were conducted as described  in section 2.1.5 and 2.1.6. XTT (2,3-
bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carbox-anilide  [Sigma, 
UK])  was prepared in media associated with each specific bacterial strain. 
 
2.1.4  A  measurement  of  efflux  pump  activity  of  pulmonary  bacteria 
using alanine β-naphthylamide (Ala-Nap) a fluorescent assay. 
An Ala-Nap fluorescent assay was performed to assess efflux pump activity, 
as previously described by Lomovskaya et al (2001). Ala-Nap is enzymatically 
cleaved  inside  the  cells  to  produce  highly  fluorescent  β-naphthylamine, 
therefore, the higher the fluorescence the lower the efflux pump activity, as 
described by Rajendran et al (2011). YHBG3, YHBG12 and YHBCC4 isolates 
were washed and standardised as described in section 2.1.3.1 to 5 × 10
5 cells 
in buffer solution (K2HPO4 [50mM], MgSO4 [1mM], and glucose [0.4%]) at pH 
7.0,  and  dispensed  into  black  flat-bottomed  microtitre  plate  (Costar  3603, 
Corning, NY). The reaction was initiated by the addition of Ala-Nap at a final 
concentration of 128 mg/L. Fluorescence was quantified at 30s intervals for 1 
h at 37
oC using a fluorescent plate reader (FLUOstar OPTIMA, BMG Labtech, 
Aylesbury, Buckinghamshire, UK) with an excitation wavelength of 320nm and 
emission of 460nm.   
 
2.1.5   Oral and pulmonary bacteria viability assay   
XTT  (Sigma)  was  prepared  in  50mL  freshly  prepared  bacterial  media  to 
produce a saturated 50 mg/L solution of XTT. The XTT solution was filtered 
through a 0.22μm filter, before using XTT for the reduction assay.  Prior to 
each  assay,  menadione  (10  mM  in  acetone)  was  added  to  a  final Chapter 2: Material & Methods 
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concentration of 1 M.  One hundred microlitres of XTT/menadione solution 
was added to each biofilm in a 96-well microtitre plate, and to the control wells 
to  measure  background  XTT-reduction  levels.  One  hundred  microlitres  of 
XTT  was  added  to  the  pre-washed  biofilms,  for  both  treated  and  control 
samples and incubated at 37
oC for 3 h. Eighty microlitres of supernatant was 
transferred by pipetting from the XTT treated 96-well microtitre plate to a fresh 
96-well microtitre plate to measure colour change in a plate reader (FLUOstar, 
Omega) at 490 nm. 
 
2.1.6   Burkholderia spp biomass assay  
Biomass assays were performed to calculate the density of Burkholderia spp 
biofilms following treatment with tigecycline ± EPI.  Remaining supernatant in 
wells were discarded after performing the XTT assay and washed with PBS 
until the biofilm became clear.  Biofilm was air dried in an incubator at 37ºC for 
1 h.  One hundred microlitres of 0.5% w/v crystal violet solution was added to 
each well and left at room temperature (RT) for 5 min. The crystal violet dye 
solution was then discarded by pipetting and residual dye washed off under 
gentle running tap water. One hundred microlitres of 100% ethanol was added 
to each well. Ethanol was mixed in each well by pipetting with the remaining 
crystal violet dye still adherent to the biofilm. Eighty microlitres of the ethanol 
from each well was transferred to a clean plate to record the biomass reading. 
This colour change was measured in a plate reader (FLUOstar, Omega) at 
570 nm. 
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2.2   Immunomodulatory effects of tigecycline 
2.2.1   Tigecycline purity assay 
Bone marrow derived dendritic cells were generated from C57BL/6 mice and 
maintained in GI 1640 media (Sigma, UK) supplemented with 1% pen strep 
(Gibco, UK), 10% foetal calf serum (Gibco, UK) and 1% L-glutamine (Gibco, 
UK).    Tigecycline  was  prepared  as  described  in  section  2.1.2  and 
standardised to 0.1, 0.4 and 1.6 mg/L in GI supplemented media.   
 
The  cell  concentration  was  standardised  to  1  x  10
5  cells/mL  in  20mL  of 
supplemented GI.  One microlitre of cell media was added to each well of a 6 
well cell culture plate (Costar, Corning Incorporated, NY, USA). Wells 1 to 3 
were inoculated with 0.1, 0.4 and 1.6 mg/L of tigecycline, well 4 with 50 mg/L 
of E.coli derived LPS and well 5 was used as control of supplemented  GI 
media only.  Inoculated cells were incubated in a humidified atmosphere for 
24 h at 37
oC at 5% CO2. 
 
Cell media was pipetted out and adherent cells were scraped from each well 
and transferred into a 15mL falcon tube.  Supernatant was spun for 5 min at 
340 g and supernantant discarded.  Cells were resuspended in 500µL FCR 
block  (Miltenyi  biotech,  Germany)  and  incubated  at  4
oC  for  15  min.    One 
hundred microlitres of supernatant from each falcon tube was transferred into 
fresh FACS tubes (Becton Dickinson, NJ, USA).  One hundred microlitres of 
each  antibody  (Ab)  was  added  to  each  falcon  tube  at  each  separate 
concentration (Ab used were Anti-CD86 (IGE-2A-FITC (Becton Dickinson, NJ, 
USA), anti-MHC II (Rat IGG-2A) FITC (Becton Dickinson, NJ, USA) and ISO Chapter 2: Material & Methods 
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(Becton  Dickinson,  NJ,  USA)  only  as  a  control.)  Ab  was  left  to  bind  to 
dendritic cells for 30 min in the dark at 4
oC.  Cells were subsequently washed 
twice in FACS buffer (2.5%FCS, PBS, 0.02% azide) and spun at 340 g for 5 
min  between  each  wash  and  supernantant  discarded.    Cells  were 
resuspended in 300µL of FACS buffer and flow cytometry was carried out on 
a FACScanto (Becton Dickinson, NJ, USA).  Flow cytometry data was then 
analysed using FLOJO software (Tree Star, USA) 
 
2.2.2   A549 Cell culture 
A549  human  lung  carcinoma  cells  were  obtained  from  the  European 
Collection  of  Cell  Cultures  (ECACC).    A549  cells  were  maintained  in 
Dulbecco’s Modified Eagles Medium (DMEM) (Sigma) containing 10% foetal 
bovine serum (Sigma, UK), supplemented with 200mM L-Glutamine, 100mg/L 
penicillin and 100mg/L streptomycin (Sigma).  Cells were seeded at 1 x 10
6 
cells/mL in 75cm
2 cell culture flasks (Greiner Bio-one, Gloucestershire, UK) in 
an  incubator  with  a  humidified  atmosphere  at  37
oC  and  5%  CO2  (C&M 
scientific, Scotland). Culture media was changed  every two days and cells 
split 1:10 during each passage at 1 x 10
6 cells/mL. 
 
Cells were washed with 10mL of prewarmed Dulbecco’s phosphate buffered 
saline (DPBS) (Sigma) and passaged at 90% confluence, with 0.5% trypsin 
EDTA (Sigma) for 5 min at 37
oC in 5% CO2.  Once detached, 15mL of DMEM 
was  added  to  flasks  to  inactivate  the  effects  of  trypsin.    The  cells  were 
standardized to a final concentration of 8 x 10
5 cells in 20 mL DMEM in 75cm
2 
flasks.  Cells  were  then  incubated  in  5%  CO2  at  37
oC  in  a  humidified Chapter 2: Material & Methods 
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atmosphere  and  experimental  procedures  undertaken  on  cells  between 
passage  9  and  16.    All  cell  culture  work  was  carried  out  in  a  sterile 
environment in a Microflow cabinet (Ervicecare, Hampshire, UK). 
 
2.2.3  Experimental procedures for A549 cell stimulation 
A549  cells  were  prepared  as  described  above  to  80-100%  confluence, 
washed and trypsinised.  Cells were then transferred to a bijoux tube and 
centrifuged  for  5  min  at  10,000  g.    Supernatant  was  discarded  and  cells 
washed with 10mL DPBS for 3 min to wash residual DMEM media from cells.  
Cells were resuspended in 2mL of DMEM and gently mixed by pipetting.   
 
Twenty  microlitres  of  the  resuspended  cell  media  was  placed  in  a  1.5mL 
centrifuge tube with 10µL Trypan Blue solution (Sigma, UK) and mixed.  10µL 
of cell media was suspended on a Naeuber haemocytometer and viable cells 
counted.  Cell culture media was standardised to 1 x 10
5 cells/mL in 20mL of 
DMEM.  One millilitre of cell media was added to each well of a 24 well cell 
culture plate (Costar, Corning Incorporated, NY, USA) and incubated for 4 h 
and 24 h at 37
oC in 5% CO2. 
 
Following  overnight  incubation,  cell  supernatant  was  removed  by  pipetting. 
Cells were stimulated in duplicate, with 500µL of media serving as a control. 
Experimental wells contained a total of 500µL of media and tigecycline at 0.1, 
0.4  or  1.6  mg/L  ±  E.  coli  derived  LPS  (Sigma)  prepared  to  a  working 
concentration of 50 mg/L.  LPS in media served as a second control. 
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2.2.4   OKF6/TERT2 Cell culture 
OKF6/TERT2 cells were provided by the Rheinwald laboratory (Brigham and 
Woman’s  Hospital,  Boston).  Cells  were  cultured  in  keratinocyte  serum-free 
medium  (K-SFM  [37010-022]  Invitrogen,  UK)  supplemented  with  100  IU 
penicillin, 100 mg/L streptomycin, 25 mg/L bovine pituitary extract (BPE), 0.2 
ng/mL epidermal growth factor (EGF) and 0.3 mM CaCl2 (0.4 mM total Ca
++). 
BPE and EGF were filter-sterilised through a 0.2 µm filter. Cells were seeded 
at 5 x 10
3/mL in a 75 cm
2 flask. At approximately 30% confluence, media was 
changed to 50% K-SFM, 25% DMEM, 25% Ham’s F12 and, supplemented as 
above with penicillin/streptomycin, 1.5 mM L-glutamine, BPE and EGF.  All 
cell  culture  work  was  carried  out  in  a  sterile  environment  in  a  Microflow 
cabinet (Ervicecare, Hampshire, UK).   Cells were passaged at approximately 
90% confluence, using 0.05% trypsin/ EDTA.  For cytokine assays, cells were 
cultured in defined-KSFM (10744-019, Invitrogen)  
 
2.2.5  Experimental procedures for OKF6/TERT2 cells 
Cell were standardised as described in Section 2.2.4,  1mL of cell media was 
added  to  each  well  of  a  24-well  cell  culture  plate  (Costar,  Corning 
Incorporated, NY, USA) and incubated for 4 h and 24 h at 37
oC in 5% CO2.   
 
Following  overnight  incubation  cell  supernatant  was  removed  by  pipetting. 
Cells were stimulated in duplicate, with 500µL of media serving as a control. 
Experimental wells contained a total of 500µL of media and tigecycline at 0.1, 
0.4 or 1.6 mg/L ± E. coli derived LPS (Sigma, UK) prepared to a working 
concentration of 50 mg/L.  LPS in media served as a second control. Chapter 2: Material & Methods 
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2.2.6   Tigecycline toxicity assay to A549 and OKF6/TERT2 cell lines 
A549 and OKF6/TERT2 cells were standardised and prepared for assays as 
described in sections 2.2.2 and 2.2.4.  Each cell line was stimulated with LPS 
±  tigecycline  as  described  in  section  2.2.3  and  2.2.5.    XTT  was  prepared 
initially as outlined in section 2.1.5   
 
To produce a saturated 50 mg/L solution of XTT for each cell line, 50mL of 
cell  media  specific  to  each  cell  line  was  used.    Two  hundred  and  fifity 
microlitres of prepared XTT was added to each well after each cell line had 
been  stimulated  for  24  h.    XTT  was  incubated  at  37
oC  for  3  h.  Eighty 
microlitres of supernatant was transferred by pipetting from the XTT treated 
wells to a fresh 96-well microtitre plate to measure colour change in a plate 
reader at 490 nm. 
 
2.2.7   Gene expression for cytokines 
 
2.2.7.1 RNA preparation from A549 and OKF6/TERT2 cells 
A549 and OKF6/TERT2 gene expression was measured by quantitative RT-
PCR.  A549 and OKF6/TERT2 cells were treated with differing concentration 
of tigecycline and a constant amount of LPS as described above.  After the 24 
h time point cells were removed from incubation and each well supernatant 
was removed and stored in cryovials at -80ºC for subsequent ELISA analysis. 
 
RNA  was  extracted  from  each  well  using  RNeasy  Mini  Kit  (Qiagen  LTD, 
Crawley,  West  Sussex,  UK)  following  manufacture’s  guidelines.    In  brief, Chapter 2: Material & Methods 
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350µL  of  Buffer  RLT  (Qiagen)  was  added  to  each  well  for  direct  lysis  of 
cellular monolayer.  Lysate was collected from each well and placed in a 1.5 
mL microcentrifuge tube. Lysate was vortexed for 10s and pipetted to ensure 
visible clumps were not present.  Three hundred and fifty microlitres of 70% 
ethanol was added to homogenize the lysate and mixed by pipetting.   Seven 
hundred  microlitres  of  sample  was  transferred  to  an  RNeasy  spin  column 
(Qiagen), placed in a 2mL collection tube (Qiagen), and centrifuged for 15s at 
10,000g.  Seven hundred microlitres  of Buffer RW1 (Qiagen) was added to 
the RNeasy spin column and centrifuged for 15s at 10,000g to wash the spin 
column membrane and flow through discarded.  Five hundred microlitres of 
Buffer RPE (Qiagen) was added to the spin column, centrifuged for 15s at 
10,000g  to  wash  the  spin  column  membrane  and  flow  through  discarded.  
Five hundred microlitres of Buffer RPE was added to the spin column and 
centrifuged for 2s at 10,000g to wash the spin column membrane and flow 
through discarded.  The RNeasy spin column was placed in a new 1.5mL 
collection tube with the addition of 50µL RNase-free water (Qiagen) directly to 
the spin column membrane and centrifuged for 1 min at 10,000g to elute the 
RNA.  Finally, to ensure a high concentration of RNA the flow through was 
added back into the spin column membrane and centrifuged again for 1 min at 
10,000g.  
 
2.2.7.2 DNase treatment of RNA samples 
To ensure RNA was clear from DNA contamination, 15µL of RNA was heated 
to 37
oC for 30 min with the addition of 2µL of 10x Buffer (Promega, UK) and 
2µL of DNase (Promega, UK).  Finally, 2µL of stop solution (Promega, UK) Chapter 2: Material & Methods 
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was added to each sample and this was incubated for a further 10  min at 
65
oC.    The  ‘clean’  RNA  was  collected  and  quantified  using  a 
spectrophotometer, described below. 
 
2.2.7.3 Quantification of nucleic acids 
Purified  RNA  (1.5µL)  was  quantified  in  a  NanoDrop
TM  ND-1000 
spectrophotometer (Labtech International, Ringmer, East Sussex UK).  The 
reference was established with sterile filtered, UV-treated ddH20 prior to RNA 
quantification.  Total RNA samples were quantified accordingly and recorded 
as ng/µL.  Samples with a 260/280 nm ratio of 1.7 to 1.8 were deemed to be 
of  high  enough  quality  for  subsequent  quantitative  PCR  reactions.    RNA 
samples were stored at -70
oC for subsequent analysis. 
 
2.2.7.4  Reverse transcription 
cDNA  was  prepared  using  superscript  ll  reverse  transcriptase  (Invitrogen, 
Paisley,  UK)  as  follows:    100ng  RNA  was  incubated  in  RNase-free  water 
(Invitrogen)  with  0.5µg  Oligo(dT)  (Invitrogen)  and  10mM  dNTP  mixture  at 
65
oC for 5 min, quick chilled, then reverse transcribed using 100U superscript 
II RT at 42
oC for 50 min in the presence of the manufacturer’s buffer (50mM 
Tris.HCL (pH 8.3), 75mM KCl, 3 mM MgCl2) with 0.01M DTT and 1µL (40 
units) RNase OUT Ribonuclease inhibitor (Invitrogen)  in a total volume of 
25µL.  Finally, the superscript was inactivated by heating to 70
oC for 15 min.  
In addition, ‘no RT’ controls were preformed in the absence of Superscript. 
The cDNA was used immediately in PCR or stored at -20
oC. 
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2.2.7.5 Real-time quantitative PCR (IL-6 and IL-8) 
1 in 20 dilutions of cDNA samples were prepared and 2µL of this was PCR-
amplified using 200nM primers (0.5µL forward and reverse primers at 10µM) 
(Table  2.3) with  12.5µL  SYBR green master mix  (Invitrogen) and  9.5µL of 
DNase/RNase free water (Qiagen, UK) to a total volume of 25µL per reaction.  
Reactions were performed in duplicate on 0.2mL optical tube strips (Agilent 
technologies) using the Mx3000P QPCR machine (Aglient technologies).   
 
A  standard  dissociation  curve  protocol  was  included  after  40  amplification 
cycles to confirm that only one product was made.  Threshold cycle (Ct) was 
determined  for  all  samples  after  carefully  selecting  appropriate  threshold.  
Amplification  plots  were  looked  at  in  the  logarithmic  scale  and  threshold 
selected  to  be  above  any  baseline  fluorescence.    In  the  region  where  the 
amplification  was  exponential  (steep  curve)  and  where  the  majority  of 
replicates  gave  very  similar  Ct  values  (i.e.  where  duplication  amplification 
plots were parallel).   
 
Expression levels of IL-6 and IL-8 were measured in relation to the house 
keeping  gene  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH).    The 
thermal profile was optimised for all primers (Tables 2.4). No RT controls were 
included  to  check  for  DNA  contamination  and  no  template  controls,  with 
RNase  free  water  (Qiagen),  were  run  to  rule  out  other  contamination 
problems. 
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Table 2.3   Primers used for analysis of pro-inflammatory mediators in 
this study 
Primers and associated primer sequences used during all pro-inflammatory 
investigations. 
Primer  Sequence  Reference 
IL-6 Forward  3’ CAATCTGGATTCAATGAGGAGAC 5’  Girault et al, 2002. 
IL-6 Reverse  3’ CTCTGGCTTGTTCTTCACTACTC 5’ 
IL-8 Forward  3’ TTAGCACTCCTTGGCAAAAC 5’  Li et al, 2007. 
IL-8 Reverse  3’ CAGAGACAGCAGAGCACACAA 5’ 
GAPDH Inner 1  3’ CAAGGCTGAGAACGGGAAG 5’  McKimmie  et  al, 
2008.  GAPDH Inner 2  3’ GGTGGTGAAGACGCCAGT 5’ 
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Table 2.4  PCR reaction conditions 
PCR reaction conditions to analyse expression of IL-6 and IL-8 from A549 and 
OKF6/TERT2 cells.  The total time for complete run ~ 142 min and consisted 
of 3 phases. 
  Temperature (
0C)       Time 
Denaturing (1 cycle) 
 
50 
95 
 
95 
56 
72 
 
72 
2  min 
10 min 
 
30 s 
30 s 
30 s 
 
10 min 
 
Amplification (40 cycles)    denature 
                                              anneal 
                                              extend 
 
Extend (1 cycle) 
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2.2.8  Cytokine  assays  using  enzyme-linked  immunosorbent  assays 
(ELISA) 
Cytokines concentrations in culture supernatants from A549 and OKF6 cell 
experiments  were  measured  by  sandwich  ELISA  using  human  IL-6  and 
human IL-8 Cytoset
TM (Biosource, USA) in accordance with manufacturer’s 
instructions.  Table 2.5 indicates solutions used in all assays.  Assays were 
optimised  and  validated  prior  to  use.  Immulon  4  HBX  flat-bottom  96-well 
microtitre plates (Fisher Scientific, UK) were coated with IL-6 or IL-8 capture 
antibody (4 g/ml in PBS), which were sealed and incubated overnight at 4ºC.  
Subsequent  incubations  were  at  carried  out  at  room  temperature.  Two 
hundred microlitres of blocking buffer was added to each well for 1 h. After the 
step  described  above  and  subsequent  steps  below,  microtitre  plates  were 
washed 5 times with wash buffer. A standard curve consisting of 7 doubling 
dilutions (range 15.63 - 1000 pg/ml) was prepared to calculate concentrations 
of IL-6 and IL-8 in the samples. One hundred microlitres of standards and 
samples were added in duplicate and incubated for 2 h,  biotinylated IL-6 or 
IL-8 detection antibody (20 ng/ml in cell culture media + 0.1% BSA +0.05% 
Tween®20)  was  added  and  incubated  for  2  h.    Streptavidin-horseradish 
peroxidase  was  added  for  20  min  and  protected  from  light.  Plates  were 
developed  with  100L  3,3,5,5’-tetra-methylbenzidine  (TMB,  R&D  Systems, 
UK).  Blue colour was allowed to develop in the dark. The final colour change 
was measured at an absorbance of 560 nm. Cytokine concentrations were 
calculated using a 4-parameter curve fit.   Graphpad Prism, version 4.0 for 
Windows (Graphpad Software, CA, USA) and was used for statistical analysis 
to determine significant changes, p values less than 0.05 Chapter 2: Material & Methods 
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Table 2.5 Duoset ELISA solutions  
ELISA solutions for IL-6, IL-8 and MMP-9 as described in section 2.2.8 
Solutions  Mixture 
PBS  PBS tablets  (Sigma) (1 per 100mL) 
Wash Buffer  0.05% Tween 20 in PBS, pH 7.2 – 7.4 (Sigma) 
Reagent 
Diluent 
1%  bovine  serum  albumin  (BSA  fraction  V) 
(Sigma) in PBS pH 7.2 – 7.4 
Substrate 
Solution 
1:1  mixture  of  Colour  Reagent  A  (H2O2)  and 
Colour Reagent B (TMB) 
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2.2.9 Experimental procedures of primary neutrophil cell cultures 
 
 
2.2.9.1 Peripheral blood neutrophil preparation 
Twenty  milliliters  venous  blood  was  collected  in  the  presence  of  250U/mL 
sodium heparin.  Twenty milliliters of Polymorphprep
TM (Fresenius, Norway) 
was  added  to  4  15mL  falcon  tubes.    Five  milliliters  of  blood  was  carefully 
layered  by  Pasteur  pipetting  ensuring  the  blood  did  not  mix  with  the 
Polymorphprep
TM.    Each  falcon  tube  containing  the  cells  and  
Polymorphprep
TM  was centrifuged at 500 x g in a swing bucket rotor for 30 
min at RT.  Plasma and mononuclear cells were removed initially from the 
interface.  Neutrophils were harvested from the lower subsequent band.  An 
equal  amount  of  PBS  (5mL)  was  mixed  with  sterile  water  (5mL)  and 
neutrophils added to the media and centrifuged at 400 x g in a swing bucket 
rotor for 10 min.  Supernatant was discarded and pellet resuspended in 5mL 
ammonium  chloride  lysis  buffer  (eBioscience,  UK)  to  remove  any  residual 
contamination of the neutrophils.  Neutrophils were centrifuged at 400 x g for 
10 min and subsequently washed 3 times in RPMI by centrifuging at 330 x g 
for 5 min at RT. 
 
  2.2.9.2 Neutrophil cytokine production in response to Tigecycline 
Neutrophils  were  added  to  a  96-well  flat  bottom  plate  (Costar),  at  2  x  10
5 
cells/mL in 100ul complete GI 1640 supplemented with 10% fetal calf serum 
(Sigma, UK).  Cells were co-stimulated in triplicate, with 1 mg/L (PMA) and 
tigecycline at 0.1, 1 and 10 and 100 mg/L respectively for 24 h at 37
oC.   
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2.2.9.3  IL-8 chemokine assay using ELISA 
IL-8  within  coculture  supernatants  from  neutrophil  cell  experiments  were 
measured by sandwich ELISA using human IL-8 Cytoset
TM (Biosource, USA) 
in accordance with manufacturer’s instructions, and carried out as described 
in section 2.2.8. 
 
2.2.9.4 Matrix metalloproteinase 9 assay using Duoset ELISA 
MMP-9  within  coculture  supernatants  from  neutrophil  cell  experiments  was 
measured by duoset ELISA using human total MMP-9 (R&D systems, USA).  
Initially the assay was optimised and validated prior to use.  
 
Immulon 4 HBX flat-bottom 96-well microtitre plates (Fisher Scientific) were 
coated  with  100µL  of  capture  antibody  diluted  to  working  concentration  in 
PBS, sealed and incubated overnight at RT.  Each well was aspirated and 
washed in 400µL of wash buffer 3 times.  One hundred microlitres of reagent 
diluent was added to each well to block the plate and incubated for 1h at RT.  
Wells were washed as described above. One hundred microlitres of standards 
prepared in reagent diluent and samples were added to wells in duplicate, and 
incubated for 2h at RT.  Plates were washed again as described above. One 
hundred  microlitres  of  detection  antibody  (4ug/ml)  diluted  to  working 
concentration in reagent diluent was added to all wells and incubated for 2 h 
at RT.  Wells were washed as described above.  One hundred microlitres of 
the working dilution of streptavidin-horseradish peroxidase was added to each 
well  and  incubated  in  the  dark  at  RT  for  20  min.  Wells  were  washed  as 
described above.  The final colour change was measured after addition of Chapter 2: Material & Methods 
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TMB substrate at an absorbance of 560 nm. A standard curve was prepared 
to calculate concentration of MMP-9 in samples (range 31.15 -2000 pg/ml) 
Cytokine  concentrations  were  calculated  using  a  4-parameter  curve  fit.  
Graphpad Prism, version 4.0 for Windows (Graphpad Software, CA, USA) and 
was used for statistical analysis to determine significant changes, p values 
less than 0.05 
 
2.2.10 Data analysis          
All  data  and  statistical  analysis  for  all  microbiological  and  immunological 
assay  were  performed  using  Graphpad  Prism,  version  4.0  for  Windows 
(Graphpad  Software,  CA,  USA) to  determine  significant  changes,  p  values 
less  than  0.05.  Non-parametric  Mann-Whitney  tests  were  employed  for  all 
microbiological results and the One-way analysis of variance (ANOVA) tests 
were performed to compare control samples with all treatments of the A549 
and OKF6/TERT2 cell lines. 
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3  Results 
 
3.1   Antimicrobial properties of tigecycline 
 
3.1.1   Introduction 
These  experiments  aimed  to  evaluate  the  activity  of  tigecycline  against 
bacterial pathogens associated with both oral and respiratory tract infections. 
This  included  Burkholderia  spp,  which  are  associated  with  chronic 
inflammatory  disease  of  the  lung,  and  Porphyromonas  gingivalis, 
Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans spp., 
which are associated with chronic inflammatory diseases of the periodontium.  
In addition it was intended to evaluate the role of multidrug efflux pumps in the 
sensitivity of tigecycline against these different bacterial pathogens. 
 
3.1.2   Effects of tigecycline against planktonic and sessile cells 
3.1.2.1 Burkholderia spp.  
These experiments evaluated the activity of tigecycline against Burkholderia 
spp.  grown  both  planktonically  and  as  sessile  biofilms  (Table  3.1).    The 
planktonic MIC (PMIC) for the B. cepacia complex ranged from 8 to 32 mg/L, 
with an MIC50 of 16 mg/L.  The PMIC of tested B. gladioli strains ranged from 
4 to 8 mg/L.  The sessile MIC (SMIC) for the B. cepacia complex ranged from 
32 to 64 mg/L, with an MIC50 of 64 mg/L.  The SMIC of the B. gladioli tested 
was 32 mg/L.   
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Table 3.1 Planktonic and sessile minimum inhibitory concentrations of 
Burkholderia cepacia spp. to tigecycline  
 
Strain  Tigecycline MIC (mg/L) 
PLANKTONIC          SESSILE 
Burkholderia cepacia 
    K 56-2 (III)  32  32 
    ATCC 117765 (III)  32  64 
YHBCC1 (II)  32  64 
YHBCC2 (II)  32  64 
YHBCC3 (II)  32  32 
YHBCC4 (II)  16  32 
YHBCC5 (III)  16  64 
YHBCC6 (III)  32  64 
YHBCC7 (III)  32  64 
YHBCC8 (III)  32  64 
YHBCC9 (III)  16  32 
YHBCC10 (III)  32  64 
YHBCC11 (III)  16  32 
YHBCC12 (III)  32  64 
          YHBCC13 (IV)  8  32 
YHBCC14 (V)  16  64 
YHBCC15 (V)  16  64 
Burkholderia gladioli 
YHBG1  8  32 
YHBG2  4  16 
YHBG3  8  32 
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3.1.2.2  Porphyromonas  gingivalis,  Fusobacterium  nucleatum  and 
Aggregatibacter actinomycetemcomitans spp.  
These experiments evaluated the activity of tigecycline against P. gingivalis, 
F. nucleatum and A. actinomycetemcomitans grown both planktonically and 
as sessile biofilms in triplicate (n=3) with respective controls  The PMIC for the 
P. gingivalis and F. nucleatum remained below the minimum concentration 
tested (≤0.25mg/L).  The PMIC of the A. actinomycetemcomitans tested was 8 
mg/L (Table 3.2).   
 
The SMIC of P. gingivalis increased from the PMIC and ranged from 2 mg/L to 
64 mg/L, with an MIC50 of 4 mg/L.   F. nucleatum resistance to tigecycline 
increased dramatically in sessile form from the PMIC with a range of 64 mg/L 
to 128 mg/L with an MIC50 of 128 mg/L.  This significant increase in resistance 
was also evident with A. actinomycetemcomitans having a SMIC of 128 mg/L 
for all strains. 
 Chapter 3: Results 
 
73 
 
Table 3.2. Planktonic and sessile minimum inhibitory concentrations of 
oral pathogens to tigecycline 
 
Strain  Tigecycline MIC (mg/L) 
PLANKTONIC  SESSILE 
Porphyromonas gingivalis 
W50  ≤0.25     2 
2111  ≤0.25     4 
2114  ≤0.25     4 
2098  ≤0.25     64 
11834  ≤0.25     32 
Fusobacterium nucleatum 
494         ≤0.25             64 
10562         ≤0.25  ≥128 
01/105 (1)             ≤0.25  ≥128 
01/105 (3)         ≤0.25  ≥128 
Aggregatibacter actinomycetemcomitans 
10981     8  ≥128 
10982     8  ≥128 
9709     8  ≥128 
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3.1.3 Quantifying efflux pump activity  
Expression of drug efflux pumps is a common resistance mechanism in Gram 
positive and negative bacteria leading to increased levels of drug resistance in 
a  vast  range  of  bacterial  species.    These  experiments  were  designed  to 
evaluate the constitutive expression of efflux activity using a fluorescent based 
uptake  assay  system  as  described  in  section  2.1.4.    Analysis  of  β-
naphthylamine  production  by  3  strains  of  Burkholderia  demonstrated 
differential efflux activity carried out in triplicate (n=3). Figure 3.1A shows a 
linear increase in fluorescence as a function of time over 60 min, owing to 
intracellular hydrolysis of Ala-Nap.  This data is summarised in a histogram in 
Figure 3.1B.  The rate of cleavage of Ala-Nap was highest in YHBG3 (MIC 8 
mg/L) compared with YHBCC4 (MIC 16 mg/L) and YHBCC12 (MIC 32 mg/L).  
Both results indicate that the lower the MIC the higher the efflux activity for a 
particular strain.   
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Figure  3.1  Quantification  of  efflux  activity  utilising  Ala-nap  uptake  by 
differential strains of Burkholderia spp. 
The Burkholderia spp evaluated by serial dilutions of tigecycline displayed a 
PMIC range of 8 – 32 mg/L (Table 3.1).  (A) Ala-Nap (128 mg/L) uptake of 
selected  strains  YHBG3,  YHBCC4  and  YHBCC12  shows  an  increase  in 
fluorescence  is  depicted  owing  to  intracellular  hydrolysis  of  Ala-Nap.    The 
greater  fluorescence  was  quantified  in  the  case  of  YHBG3  (Burkholderia 
gladioli), with a MIC of 8 mg/L, indicating low efflux activity. In the case of 
YHBCC4 (MIC = 16mg/L) and YHBCC12 (MIC = 32mg/L), less fluorescence 
was  quantified  owing  to  high  efflux  activity.  (B)  Bar  graph  demonstrating 
relative fluorescent units (RFU) for each strain.  A significant increase in efflux 
activity was associated with an increase in MIC (p<0.005). 
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3.1.4  Effects  of  efflux  pump  inhibitor  (MC-207,110)  upon  tigecycline 
sensitivity 
These experiments were designed to evaluate the contribution of efflux pumps 
to  tigecycline  sensitivity.  An  EPI,  which  acts  as  a  competitive  substrate 
inhibitor, was used in combination with planktonic and sessile cells and the 
MIC’s  determined  as  described  in  section  2.1.3.3.    All  experiments  were 
carried out in triplicate (n=3) with no treated cells representing the controls  
 
3.1.4.1 Burkholderia spp. 
The PMIC for the B. cepacia complex treated with tigecycline ranged from 
<0.125 to 1 mg/L, with an MIC50 of 1 mg/L (Table 3.1).  In comparison to those 
treated with only tigecycline in the presence of EPI tigecycline demonstrated a 
significant increase in sensitivity (p<0.001), representing approximately a 37-
fold change (Figure 3.2A).  The PMIC of the B. gladioli tested ranged from 
<0.125  to  0.25  mg/L.    Planktonic  B.  gladioli  treated  with  tigecycline  in  the 
presence of EPI also demonstrated significantly increased sensitivity (p<0.01), 
with a 32-fold change compared to tigecycline alone (Figure 3.1B). 
 
The SMIC for the B. cepacia complex ranged from 0.5 to 4 mg/L, with an 
MIC50  of  2  mg/L  (Table  3.1).    In  the  sessile  form,  sensitivity  was  also 
significantly increased (p<0.0001) in the presence of EPI, representing a 26-
fold change in comparison to tigecycline alone (Figure 3.3A).  The SMIC of 
the B. gladioli tested was 2 mg/L with a 4-fold change when exposed to EPI 
and significantly increased sensitivity (p<0.001) (Figure 3.2B).  
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Table  3.3.  Effects  of  a  competitive  substrate  (MC-207,110)  of  efflux 
pumps on the sensitivity of Burkholderia cepacia sp. to tigecycline  
 
 
 
 
Strain 
Planktonic 
tigecycline MIC (mg/L) 
Sessile 
tigecycline MIC (mg/L) 
MC-
207,110 
(64 
mg/L) 
Fold-
change 
MC-
207,110 
(64 
mg/L) 
Fold-
change 
Burkholderia cepacia complex (genomovar) 
K 56-2 (III)  0.5  64  1  32 
ATCC 117765 (III)  1  32  0.5  128 
YHBCC1 (II)  1  32  1  64 
YHBCC2 (II)  1  32  1  64 
YHBCC3 (II)  0.5  64  1  32 
YHBCC4 (II)  0.5  32  1  32 
YHBCC5 (III)  0.25  64  1  64 
YHBCC6 (III)  1  32  2  32 
YHBCC7 (III)  1  32  2  32 
YHBCC8 (III)  1  32  2  32 
YHBCC9 (III)  0.25  64  4  8 
YHBCC10 (III)  1  32  2  32 
YHBCC11 (III)  0.5  32  1  32 
YHBCC12 (III)  <0.125  >128  2  32 
YHBCC13 (IV)  0.5  16  2  16 
YHBCC14 (V)  0.25  64  2  32 
YHBCC15 (V)  1  16  4  16 
Burkholderia gladioli 
YHBG1  0.25  32  2  16 
YHBG2  0.25  16  2  8 
YHBG3  <0.125  >128  2  16 Chapter 3: Results 
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Figure  3.2. Efflux  pump  inhibitor  (MC-207,110)  enhances  sensitivity  of 
planktonic  Burkholderia  spp.  to  tigecycline  after  24  h  exposure. 
Planktonic (A) B. cepacia and (B) B. gladioli were exposed to serial doubling 
dilutions of tigecycline ± MC-207,110 and incubated for 24 h at 37
oC. The 
data represent the mean and standard deviation of three experiments (n=3) 
performed in triplicate. The MIC was determined based on inhibition of growth 
when  visualised  in  a  96  well  plate.  A  significant  reduction  in  tigecycline 
concentration inhibited growth of planktonic B. cepacia in the presence of MC-
207,110  (64  mg/L)  by  approximately  37-fold  (p<0.001),  and  a  significant 
reduction in tigecycline concentration inhibited growth of planktonic B. gladioli 
in the presence of MC-207,110 (64 mg/L) by 32-fold (p<0.01).   
A 
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Figure  3.3. Efflux  pump  inhibitor  (MC-207,110)  enhances  sensitivity  of 
sessile Burkholderia spp. to tigecycline after 24 h exposure. Sessile (A) 
B.  cepacia  and  (B)  Burkholderia  gladioli  were  exposed  to  serial  doubling 
dilutions of tigecycline ± MC-207,110 and incubated for 24 h at 37
oC. The 
data represent the mean and standard deviation of three experiments (n=3) 
performed in triplicate The sessile MIC was determined based on metabolic 
reduction  within  a  96  well  plate.  A  significant  reduction  in  tigecycline 
concentration inhibited growth of sessile B. cepacia in the presence of MC-
207,110  (64  mg/L)  by  approximately  26-fold  (p<0.0001),  and  a  significant 
reduction in tigecycline concentration inhibited growth of planktonic B. gladioli 
in the presence of MC-207,110 (64 mg/L) by 14-fold (p<0.001). 
 
A 
0 10 20 30 40 50 60
TIG
TIG + EPI *
 MIC (mg/L)
 
B 
0 10 20 30
TIG
TIG + EPI *
 MIC (mg/L)
 Chapter 3: Results 
 
81 
 
3.1.4.2  Effects  of  efflux  pump  inhibitor  (MC-207,10)  upon  tigecycline 
sensitivity to oral bacteria after 24 h. 
The PMIC of P. gingivalis and F. nucleatum remained below detectable levels 
≤0.25mg/L  (Table  3.4.)    In  comparison  to  planktonic  A. 
actinomycetemcomitans treated only with tigecycline, there was a significant 
(p<0.0001)  increase  in  sensitivity  in  the  presence  of  EPI,  representing 
approximately an 8-fold change and an MIC of 1 mg/L (Figure 3.4).   
 
SMIC of P. gingivalis ranged from ≤0.25 to 8 mg/L with an MIC50 of 1 mg/L 
(Figure 3.5)  A slight reduction in sensitivity to tigecycline is demonstrated by 
the addition of MC-207,110 (64 mg/L) by approximately 2-fold (p<0.05).  A 
significant reduction in tigecycline concentration inhibited growth of sessile A. 
actinomycetemcomitans in the presence of MC-207,110 (64 mg/L) by 5-fold 
(p<0.001), with a SMIC between 8 and 32 mg/L and a MIC50 of 8 mg/L.  In 
contrast  to  these  results,  a  small  reduction  of  tigecycline  concentration  is 
observed to inhibit growth of F. nucleatum in the presence of MC-207,110 (64 
mg/L),  with  a  SMIC  ranging  between  16  and  ≥128  mg/L,  which  are  not 
statistically  different.    All  experiments  were  carried  out  in  triplicate  (n=3), 
controls were represented by bacterial cells treated with media only, 
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Table  3.4.  Effects  of  a  competitive  substrate  (MC-207,110)  of  efflux 
pumps on the sensitivity of oral pathogens to tigecycline  
 
 
 
 
Strain 
Planktonic 
tigecycline MIC (mg/L) 
Sessile 
tigecycline MIC (mg/L) 
MC-
207,110 
(64 
mg/L) 
Fold-
change 
MC-
207,110 
(64 
mg/L) 
Fold-
change 
Porphyromonas gingivalis 
W50  ≤0.25  n/a  1  1 
2111  ≤0.25  n/a  1  4 
2114  ≤0.25  n/a  ≤0.25  4 
2098  ≤0.25  n/a  8  8 
11834  ≤0.25  n/a  4  8 
Fusobacterium nucleatum 
494  ≤0.25  n/a  16  4 
10562  ≤0.25  n/a  ≥128  0 
01/105 (1)  ≤0.25  n/a  ≥128  0 
01/105 (3)  ≤0.25  n/a  ≥128  0 
Aggregatibacter actinomycetemcomitans 
10981  1  8  32  4 
10982  1  8  32  4 
9709  1  8  8  16 
 
n/a – none applicable, no fold change observed. 
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Figure  3.4  Efflux  pump  inhibitor  (MC-207,110)  enhances  sensitivity  of 
planktonic Aggregatibacter actinomycetemcomitans to tigecycline after 
24 h exposure. A. actinomycetemcomitans was exposed to serial doubling 
dilutions of tigecycline ± MC-207,110 and incubated for 24 h at 37
oC. The 
data represent the mean and standard deviation of three experiments (n=3) 
performed in triplicate.  The MIC was determined based on inhibition of growth 
when visualised in a 96 well plate. A significant reduction in tigecycline was 
required  to  inhibit  growth  of  planktonic  A  actinomycetemcomitans  in  the 
presence of MC-207,110 (64 mg/L) by 8-fold (p<0.0001). 
0 2 4 6 8 10
TIG
TIG + EPI *
MIC (mg/L)
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Figure  3.5  Effects  of  efflux  pump  inhibitor  (MC-207,10)  on  tigecycline 
sensitivity to sessile oral bacteria after 24 h.  Sessile (A) P. gingivalis (B) 
F.  nucleatum  and  (C)  A.  actinomycetemcomitans  were  exposed  to  serial 
doubling dilutions of tigecycline ± MC-207,110 and incubated for 24 h at 37
oC. 
The data represent the mean and standard deviation of three experiments 
(n=3)  performed  in  triplicate.  The  sessile  MIC  was  determined  based  on 
metabolic  reduction  within  96-well  plate.  A  slight  reduction  in  tigecycline 
concentration inhibited growth of sessile P. gingivalis in the presence of MC-
207,110  (64  mg/L)  by  approximately  2-fold  (p<0.05),  and  a  significant 
reduction  in  tigecycline  concentration  inhibited  growth  of  sessile    and  A. 
actinomycetemcomitans in the presence of MC-207,110 (64 mg/L) by 5-fold 
(p<0.001).    In  contrast  to  these  results,  a  small  reduction  of  tigecycline 
concentration is observed inhibiting growth of F. nucleatum in the presence of 
MC-207,110 (64 mg/L), this data was not statistically different. 
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3.1.5 Biofilm disruptive effects of tigecycline on bacterial biofilms.   
This  experiment  was  designed  to  determine  whether  tigecycline  had  an 
impact  on  biofilm  stability,  and  whether  homeostatic  control  of  the  biofilm 
through  inhibition  of  efflux  mediated  detoxification  in  combination  with 
tigecycline had any detrimental effects on sessile Burkholderia spp biofilm. 
Strains were grown as described in section 2.1.3.4.  EPI alone did not affect 
the biomass of the Burkholderia spp as shown by the biomass >100% (Figure 
3.5).    In  comparison  to  EPI  alone,  tigecycline  8  mg/L  ±  EPI  results  in 
significant  reduction  of  biomass  (p<0.0001).  Tigecycline  at  2  mg/L  did  not 
show  any  significant  reduction  of  the  biomass,  as  many  strains  exhibited 
>100%  biomass.  However,  2  mg/L  in  the  presence  of  EPI  resulted  in  a 
significant difference in comparison to EPI alone (p<0.0001). 
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Figure 3.6 Tigecycline disrupts sessile Burkholderia cepacia spp. in a 
concentration  dependant  manner,  which  is  improved  with  EPI  .  17 
strains  of  B.  cepacia  spp  were  exposed  to  serial  doubling  dilutions  of 
tigecycline ± MC-207,110 and MC-207,110 (64 mg/L) incubated for 24 h at 
37
oC. The data are shown as box and whisker plots and represent the median 
and quartiles of six experiments (n=6).  A significant reduction in tigecycline 
was required to inhibit growth of sessile Burkholderia spp in the presence of 
MC-207,110 (64 mg/L).  8 mg/L and 2 mg/L represent the MIC50 of the sessile 
forms of Burkholderia spp ± MC-207,110. (p<0.0001). 
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3.2 Immunological properties of tigecycline 
3.2.1 Introduction 
These experiments were designed to evaluate the effects of tigecycline on two 
inflammatory mediators IL-6 and IL-8, which was achieved by co-stimulating 
several cell lines in the presence of tigecycline, as described in section 2.2.3, 
2.2.5  and  2.2.9.    qRT-PCR  and  ELISAs  were  performed  to  quantify 
inflammatory outputs to several key cytokines and chemokines.  The purity of 
tigecycline  provided  was  assayed  by  FACS  (Figure  3.8)  to  ensure  that  no 
contaminants were present in the drug that could adversely affect the results 
of subsequent cellular work, as described in section 2.2.1.  To determine if 
any of these concentrations of tigecycline were toxic to the cell lines an XTT 
assay was carried (Figure 3.9) out as described in section 2.2.6 to ensure 
results were valid and accurate. 
    
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3: Results 
 
89 
 
3.2.2 Production of IL-8 derived from A549 cell line exposed to a range of 
LPS concentrations. 
This experiment was conducted to determine the relative amount of LPS to be 
used throughout all cellular investigations.  The A549 cell line was prepared 
and  maintained  as  described  in  section  2.2.2,  and  ELISAs  carried  out  as 
described  in  section  2.2.8.  The  assay  was  carried  out  in  duplicate  and 
represent the mean and standard deviation of three experiments (n=3) and all 
data  analysis  was  preformed  as  described  in  section  2.2.10.    The  data 
summarised  in  Figure  3.7  demonstrated  that  an  increase  in  bacterial  LPS 
resulted in a significant increase of IL-8 expression (P<0.05) 
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Figure 3.7 IL-8 protein expression from A549 cell line after exposure to 
varying ranges of LPS after 24 h.  A549 cell line was stimulated with 0 – 200 
mg/L of LPS for 24 h in microaerophillic conditions (5% CO2) supernatant was 
harvested  and  the  concentration  of  IL-8  determined  for  each  sample 
quantified  using  ELISA.    Experiment  was  carried  out  in  duplicate  and 
represent the mean and standard deviation of three experiments (n=3).  An 
increase of LPS concentration resulted in an increase of IL-8 expression from 
the A549 cell line.  Stimulation with 200 mg/L LPS resulted in the highest 
levels of IL-8 production, 10 mg/L LPS represent the lowest production levels 
of  IL-8.  Each  concentration  increase  of  LPS  (~  double)  resulted  in 
approximately a 2-fold increase of IL-8 expression.   
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3.2.3  Fluorescence-activated  cell  sorting  in  the analysis  of  tigecycline 
purity 
The experiment was designed to determine if the tigecycline powder provided 
was  free  of  endotoxin  that  could  adversely  affect  the  results  of  cellular 
experiments.  The dendritic cells were generated from bone marrow cells of 
C57BL/6 mice which were grown within the GBRC at Glasgow University by 
Mr  John  Butcher  on  my  behalf.    Dendritic  cells  were  stimulated  with  LPS 
showed an upregulation of both CD86 (Figure 3.8A) and MHC II (Figure 3.8B) 
markers  on  the  cell  surface.    When  stimulated  with  varying  ranges  of 
tigecycline,  no  upregulation  of  either  marker  was  evident,  therefore  it  was 
concluded that tigecycline powder was pure and free of LPS contaminants. 
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Figure  3.8  Analysis  of  CD86  and  MHC  II  by  FACS  analysis  when 
stimulated with tigecycline  
Dendritic  cells  were  grown  overnight,  antibodies  were  conjugated  to  the 
flurochrome fluorescein isothiocyanate (FITC) to allow for specific binding to 
dendritic  cell  markers  (A)  CD86  and  (B)  MHC  II  followed  by  subsequent 
stimulation with LPS 50 mg/L and 0.1 mg/L (Panel X), 0.4 mg/L (Panel Y) and 
1.6 mg/L (Panel Z) of tigecycline and incubated in microaerophillic conditions 
(5% CO2) at 37
oC for 24 h.  (A) CD86 and (B) MHC II controls were both up 
regulated when dendritic cells were stimulated with LPS (far left graphs for A 
and B).  The blue lines on the graphs represent the dendritic cells stimulated 
with LPS compared to the red line which represent the control set of dendritic 
cells that were not stimulated.  The right shift in fluorescence of B equates to 
increased cell numbers detected by the antibodies. 
 
 
 
Control       Panel X           Panel Y      Panel Z 
Control       Panel X           Panel Y      Panel Z 
 Chapter 3: Results 
 
93 
 
3.2.4  Tigecycline  concentration  does  not  adversely  affect  A549  and 
OKF6/TERT2 cell lines.  
These experiments were conducted to determine if exposure to tigecycline 
elicited a detrimental effect on the metabolic activity of each cell line.  A549 
and OKF6/TERT2 cells were cultured as described in section 2.2.2 and 2.2.4 
and  the  experiment  conducted as  described  in  section  2.2.6. Treatment  of 
A549 (Figure 3.8A) and OKF6/TERT2 (Figure 3.8B) with LPS and tigecycline 
did not result in any significant reduction in metabolic activity after 24 h. 
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Figure 3.9 LPS and tigecycline do not adversely affect the metabolic activity of A549 and OKF6/TERT2 cell lines 
after 24 h incubation. 
(A) A549 and (B) OKF6/TERT2 cell lines were stimulated with 0.1 mg/L, 0.4 mg/L and 1.6 mg/L of tigecycline, DMEM and 
defined-KSFM media alone served as a negative controls for A549 and OKF6/TERT2 cells respectively, LPS (50 mg/L) 
serving as a positive control.  The experiments were all carried out in duplicate and represent the mean and standard 
deviation  of  three  experiments  (n=3).  There  was  variability  between  both  cell  lines,  however  there  was  no  significant 
reduction of metabolic activity associated with either cell line when stimulated with LPS and varying ranges of tigecycline. 
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3.2.5 Immunomodulatory effects of tigecycline upon IL-6 production by a 
pulmonary and oral epithelial cell line. 
These experiments were designed to evaluate the immunomodulatory activity 
of tigecycline against the synthesis of pro-inflammatory cytokine IL-6 by the 
pulmonary cell line (A, B) A549 and (C, D) oral cell line OKF6/TERT (Figure 
3.10 – 3.11).  Cells were stimulated with tigecycline at 0.1 mg/L, 0.4 mg/L and 
1.6 mg/L ± 50 mg/L of E.coli derived LPS for (A, C) 4 h  and (B, D) 24 h.  To 
ensure  reliability  all  experiments  were  carried  out  in  duplicate  on  three 
separate occasions, after 4 and 24 h cell supernatant were stored for analysis 
with ELISA and genomic material harvested for analysis by RT-qPCR.    
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Figure  3.10  IL-6  mRNA  expression  after  exposure  to  varying 
concentrations of tigecycline ± LPS after 4 and 24 h.  
Figure  3.10(A).  After  4  h  tigecycline  treated  A549  cells  expressed 
approximately the same levels of IL-6 when compared to the media control, in 
contrast,  tigecycline  +  LPS  (0.1  /  1.6  mg/L)  induced  an  8-fold  and  5-fold 
increase in IL-6 expression respectively when compared to the LPS control.  
This data was not significantly different. 
 
Figure 3.10(B).  At the 24 h time point IL-6 expression of tigecycline treated 
A549  cells  showed  similar  levels  of  expression  to  the  LPS  control,  with 
exception  to  tigecycline  0.4  mg/L.    Tigecycline  +  LPS  treated  A549  cells 
demonstrated  a  marked  decrease  in  IL-6  expression  at  all  concentrations.  
Resulting in a significant 4-fold reduction compared to the 4 h time point and 
significantly  different  when  compared  to  the  LPS  control  (p<0.05)  The 
decrease in the levels of expression were similar to the media control, with 
exception to tigecycline 1.6 mg/L + LPS treated cells. 
 
Figure 3.10(C).  OKF6 cells stimulated with tigecycline at 0.1 and 0.4 mg/L 
both increased expression of IL-6 transcripts by 14-fold, those cell treated with 
tigecycline  at  1.6  mg/L  producing  a  20-fold  increase  in  expression  when 
compared to the media control.  When the cell-line was co-stimulated with 
tigecycline 0.1, 0.4 and 1.6 mg/L + LPS, lower levels of IL-6 expression were 
observed when compared to the tigecycline (only) treated cells.   This data 
was not statistically different. 
 
Figure 3.10(D).  IL-6 expression after 24 h was reduced considerably when 
compared to the 4 h time point for all treatments with tigecycline alone. All 
three  concentrations  caused  almost  a  6-fold  reduction  in  expression. 
Tigecycline 0.1 mg/L + LPS also caused a reduction by 3-fold.  Expression 
levels of IL-6 in all cells treated were not significantly different to the media 
control.   
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Experiment  were  carried  out  in  duplicate  and  represent  the  mean  and 
standard deviation of three experiments (n=3). 
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Figure 3.11 IL-6 protein expression after exposure to varying ranges of 
tigecycline ± LPS after 4 AND 24 h.   
Figure 3.11(A).  IL-6 protein expression levels after 4 h from A549 cell line 
resulted in low levels of expression for all experimental  parameters.  Cells 
treated  with  tigecycline  at  0.1  -  1.6  mg/L  represented  a  dose  dependent 
increase of IL-6 which was lower than the LPS control.  Stimulation of cells 
with  tigecycline  0.1  mg/L  and 0.4 mg/L  +  LPS  resulted  in  similar levels of 
expression as the LPS control.  Cell treated with tigecycline 1.6 mg/L + LPS 
appeared to have higher levels of expression of IL-6 when compared to the 
LPS control. This data was not significantly different. 
 
Figure 3.11(B).  After 24 h of stimulation with tigecycline 0.1 - 1.6 mg/L the 
cells had decreased levels of IL-6 expression. This data was also the case for 
those  cells  treated  with  tigecycline  0.1  -  0.4  mg/L  +  LPS.  However,  cells 
treated with tigecycline 1.6 mg/L + LPS appeared to have higher levels of 
expression  of  IL-6  when  compared  to  the  LPS  control.  This  data  was  not 
significantly different. 
 
Figure 3.11(C).  After 4 h IL-6 protein expression by the OKF6 cell-line treated 
with tigecycline at 0.1 mg/L displayed expression levels similar to the media 
control, but higher than that of the LPS-stimulated cells control.  Cells treated 
with tigecycline at 0.4  mg/L and 1.6 mg/L expressed similar levels of IL-6, 
however, they expressed lower levels of IL-6 when compared to the LPS and 
media controls.  Cells treated with tigecycline at 0.1 - 1.6 mg/L + LPS all had 
similar IL-6 expression levels as the LPS control (60 pg/mL).  This data was 
not significantly different. 
 
Figure 3.11(D).  Following 24 h treatment the media control expression levels 
had reduced by approximately 2-fold and the LPS control had increased by 25 
pg/mL above the 4 h time point.  IL-6 expression levels of cells stimulated with 
tigecycline at 0.1 mg/L, 0.4 mg/L and 1.6mg/mL were all lower than the LPS 
control, this reduction was not statistically significant.  Cells stimulated with Chapter 3: Results 
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tigecycline 0.1 - 1.6 mg/L + LPS all had significantly increased levels of IL-6 
after 24 h when compared to the LPS control and 4h time point (p<0.05). 
 
 
Experiment  were  carried  out  in  duplicate  and  represent  the  mean  and 
standard deviation of three experiments (n=3). 
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3.2.6  Immunomodulatory  effects  of  tigecycline  upon  IL-8  produced  by  
pulmonary and oral epithelial cell lines. 
These experiments were designed to evaluate the immunomodulatory activity 
of tigecycline against the synthesis of pro-inflammatory chemokine IL-8 by the 
pulmonary cell line (A, B) A549 and (C, D) oral cell line OKF6/TERT (Figure 
3.12 – 3.13).  Cells were stimulated with tigecycline at 0.1 mg/L, 0.4 mg/L and 
1.6 mg/L ± 50 mg/L of E.coli derived LPS for (A, C) 4 h and (B, D) 24 h  To 
ensure  reliability  all  experiments  were  carried  out  in  duplicate  on  three 
separate occasions, after 4 and 24 h cell supernatant were stored for analysis 
with ELISA and genomic material harvested for analysis by RT-qPCR.    Chapter 3: Results 
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Figure 3.12 IL-8 mRNA expression after exposure to varying ranges of 
tigecycline ± LPS after 4 and 24 h.   
Figure  3.12(A).  IL-8  mRNA  expression  of  the  A549  cell  line  after  4  h 
stimulation with tigecycline at 0.1 and 0.4 mg/L had similar expression levels 
as the LPS control, in contrast cells treated with tigecycline at  1.6 mg/L  were 
3-fold higher than the LPS control. Cells treated with tigecycline at 0.1 - 1.6 
mg/L + LPS all had higher abundance of IL-8 transcripts when compared to 
media and LPS controls.  When compared to the LPS control cells treated 
with tigecycline at 0.1, 0.4 and 1.6 mg/L + LPS had a 4-fold, 3-fold and a 5-
fold higher expression, respectively, however this data was not significant. 
 
Figure 3.12(B).  After 24 h cells stimulated with tigecycline at 0.1, 0.4, and 1.6 
mg/L IL-8 mRNA expression levels had reduced by 3-fold, 3-fold, and 6-fold 
respectively  when  compared  to  the  4  h  time  point.  Cells  treated  with 
tigecycline at 0.1, 1.4 and 1.6 mg/L had lower levels of expression compared 
to media and LPS.  Cells treated with tigecycline 0.1, 0.4 and 1.6 mg/L + LPS 
IL-8  gene expression had  reduced  by  7-fold,  5-fold and  6-fold  respectively 
when compared to the 4 h time point, this data was not significantly different. 
 
Figure 3.12(C).  OKF6 cells treated with tigecycline 0.1 - 1.6 mg/L had similar 
expression  levels  of  IL-8  mRNA  compared  to  the  media  control  after  4  h.  
Treatment of cells with tigecycline at 0.1 - 0.4 mg/L + LPS have slightly higher 
levels of expression when compared to the media control and those samples 
without  treatment  of  LPS,  however,  all  samples  have  approximately  3-fold 
reduction of IL-8 expression when compared to the LPS control, this data was 
not significantly different. 
  
Figure 3.12(D).  After 24 h the LPS control had reduced by 2-fold compared to 
4 h. Cells treated with tigecycline at 0.1 and 1.6 mg/L expressed lower levels 
of  IL-8  mRNA  compared  to  media  control.    Levels  of  expression  for  cells 
treated with tigecycline 0.4 and 1.6 mg/L  + LPS were approximately the same 
as the media control, tigecycline 0.1 mg/L + LPS had increased by 4-fold from 
4 h expressing a 2-fold increase when compared to the LPS control at 24 h, 
this data was not significantly different. Chapter 3: Results 
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Experiment  were  carried  out  in  duplicate  and  represent  the  mean  and 
standard deviation of three experiments (n=3). 
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Figure 3.13 IL-8 protein expression after exposure to varying ranges of 
tigecycline ± LPS after 4 and 24 h.  
Figure 3.13(A).  Lower levels of IL-8 protein were expressed by the A549 cell 
line after treatment with tigecycline 0.1 to 1.6 mg/L after 4 h when compared 
to the LPS control (p<0.05).  Tigecycline 0.1, 0.4 and 1.6 mg/L reduced IL-8 
levels 4-fold, 4-fold and 2-fold, respectively.  Cells stimulated with tigecycline 
0.1  to  1.6  +  LPS  all  expressed  moderate  increases  in  IL-8  protein  when 
compared to the LPS control and those cells treated with tigecycline 0.1 - 1.6 
mg/L.   
 
Figure 3.13(B).  After 24 h the LPS control had increased IL-8 levels by 3-fold 
compared to levels detected at 4 h, Cell treated with tigecycline 0.1, 0.4 and 
1.6 mg/L exponentially increased in IL-8 expression by 4-fold, 3-fold and 2-
fold respectively compared to levels at 4 h, all levels remained lower than the 
LPS control.  Treated cells with tigecycline 1.6 mg/L + LPS had similar levels 
of protein expression compared to the LPS control.  The cells treated with 
tigecycline  0.1  and  0.4  mg/L  +  LPS  had  marginally  lower  and  higher  IL-8 
levels  than  the  LPS  control,  respectively,  this  data  was  not  significantly 
different.  
 
Figure 3.13(C).  After 4 h line media control and LPS control of the OKF6 cell 
had similar levels of expression.  Cells treated with tigecycline 0.1 and 1.6 
mg/L  had  the  same  levels  of  expression  as  the  LPS  control.    Expression 
levels of cells treated with tigecycline 0.4 mg/L were elevated when compared 
to the LPS control.  Stimulation of cells with tigecycline 0.1 and 0.4 mg/L + 
LPS had the highest levels of IL-8 expression and tigecycline 1.6 mg/L + LPS 
had the lowest levels of expression; marginally lower than the LPS control. 
This data was not significantly different. 
 
Figure  3.13(D).    At  24  h  cells  treated  with  tigecycline  0.1  -  1.6  mg/L  all 
demonstrate significantly lower expression levels of IL-8 when compared to 
LPS control, and had slightly higher levels when compared to measurements 
at 4 h (p<0.05).  Cells treated with tigecycline 0.1 and 0.4 mg/L + LPS had 
both increased by 10-fold compared to 4h time point, those stimulated with Chapter 3: Results 
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tigecycline at 1.6 mg/L + LPS had increased IL-8 levels 15-fold compared with 
expression at 4 h and showed a marginal increase in IL-8 expression when 
compared to the LPS control, this data was not significantly different. 
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Experiment  were  carried  out  in  duplicate  and  represent  the  mean  and 
standard deviation of three experiments (n=3). 
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3.2.7  Immunomodulatory  effects  of  tigecycline  upon  IL-8  and  MMP-9 
production by human neutrophils. 
These  experiments  aimed  to  investigate  the  immunomodulatory  effects 
tigecycline had upon the synthesis of pro-inflammatory mediators IL-8 (Figure 
3.14A) and MMP-9 (Figure 3.14B) produced by human neutrophils during an 
inflammatory  response  as  described  in  section  2.2.9.  An  increase  of 
tigecycline reduced expression of IL-8 and MMP-9 synthesis when neutrophils 
were costimulated with 1 mg/L phorbol 12-myristate acetate (PMA)  
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Figure 3.14 Immunomodulatory effects of tigecycline to IL-8 and MMP-9 produced by human neutrophils in the 
presence  of  1  mg/L  PMA.    Human  neutrophil  cells  were  stimulated  with  0  mg/L,  0.1  mg/L,  1  mg/L  and  10  mg/L  of 
tigecycline + PMA (1 mg/L) for 24 hr in microaerophilic conditions (5% CO2) at 37
oC.  The experiment was carried out in 
triplicate (n=2). The supernatant was harvested and the concentration of (A)  IL-8 and  (B) MMP-9 determined for each 
sample quantified using antibody specific ELISA.  A 10-fold increase of tigecycline concentration inhibited expression of IL-8 
and MMP-9 in a dose dependent manner when co-stimulated with 1 mg/L PMA compared to the negative control. 
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4 Discussion 
4.1 Introduction 
CF  is  a  disease  characterised  by  bacterial  biofilm  infection  and  chronic 
inflammation  of  the  airways,  management  of  which  is  both  complex  and 
multifactorial.  Therefore,  establishing  new  ways  of  treating  this  chronic 
condition with fewer medications is attractive both for the patient, clinician and 
from  an  economic  standpoint.  This  study  has  evaluated  a  compound, 
tigecycline, which potentially has the capacity as an antibacterial agent and 
anecdotally  as  an  immunomodulatory  agent.  The  data  from  this  study  has 
shown that tigecycline has limited activity against planktonic B. cepacia, which 
is contributed to the activity of efflux pump mediated resistance. This is further 
compounded when B. cepacia is growing in a biofilm, which was associated 
with high-level resistance. Conversely, analysis of stimulated epithelial cells 
and  human  neutrophils  demonstrated  down-regulation  of  inflammatory 
mediators,  indicating  a  potential  use  in  CF.  Moreover,  given  the  exquisite 
sensitivity  of  pathogens  associated  with  periodontal  disease  to  tigecycline, 
another  chronic  inflammatory  disease,  then  there  is  a  potential  for  the 
compound to be used in the management of periodontitis. These findings will 
now be discussed.  
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P. aeruginosa and B. cepacia aggregate in mixed biofilms in the lungs of CF 
patients, both are problematic due to their biofilm forming capacity (Riedel et 
al, 2002; TomLin et al 2005). It is well documented that P. aeruginosa exhibits 
resistance  to  tigecycline.  Cheng  et  al  (2005)  identified  that  96%  of  P. 
aeruginosa  isolates  tested  exhibited  degrees  of  resistance  to  tigecycline 
MIC90  16  mg/L.  However,  the  same  study  also  reported  that  67%  of  B. 
cenocepacia isolates which is a member of the Burkholderia cepacia complex 
(Bcc) as is B. cepacia were sensitive to tigecycline (Cheng et al, 2005).  This 
is  inconsistent  with  the  data  reported  herein,  which  indicated  that  both 
planktonic  and  sessile  B.  cepacia  and  B.  gladioli  of  different  genovars  all 
exhibited  some  degree  of  resistance  to  tigecycline  (n=20).    This  finding  is 
interesting  and  clinically  relevant  as  multidrug  resistant  B.  cepacia  have 
emerged as a major infection control challenge for CF carers (Govan et al, 
1996). This was therefore investigated to elucidate a potential mechanism of 
resistance.  
Resistance  to  antibiotic  therapy  is  generally  mediated  by  the  RND  type 
transporters present in many bacterial species (Hasdemir, 2007, Chan et al, 
2003). Given that tigecycline efflux pump activity had been reported to be 
involved in P. aeruginosa PA01 resistance previously, then it was a logical 
starting point for B. cenocepcia (Dean et al, 2003; Guglierame et al, 2006). 
Moreover, Peleg et al (2007) identified bloodstream isolates of Acinetobacter 
baumannii with reduced susceptibilities to tigecycline. Peleg et al identified 
that tigecycline susceptible and non-susceptible isolates had a gene coding 
for the transmembrane component of the AdeABC efflux pump, adeB, and the 
two-component  regulatory  system  comprising  adeS  and  adeR.    They  also Chapter 4: Discussion 
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identified  point  mutations  in  the  regulatory  system  in  tigecycline  non-
susceptible isolates, indicating that an efflux-based mechanism plays a role in 
reduced  tigecycline  susceptibility  of  A.  baumannii  (Peleg  et  al,  2007).  
Salmonella  enterica  strains  have  also  exhibited  decreased  susceptibility  to 
tigecycline; the involvement of multidrug efflux pumps and AcrAB regulators 
are responsible for resistance to tigecycline (Horiyama et al, 2010). 
Horiyama et al investigate the mechanisms by which efflux pumps inhibited 
those  systems,  using  a  broad  spectrum  efflux  pump  inhibitor  MC-207,110. 
These experiments are based on work conducted by Lomovskaya et al (2001) 
in which they identified and characterised inhibitors of multidrug resistance 
efflux pumps in P. aeruginosa.  In their investigation a broad-spectrum EPI 
was used that was active against all three known Mex efflux pumps from P. 
aeruginosa MC-207,110.  Previous studies have demonstrated MC-207,110 
as  a  potential  inhibitor  of  efflux  pumps  in  Gram-negative  bacteria  that 
potentiated the activities of levofloxacin and chloramphenicol (Lomovskaya, 
2001). However, according to Chan et al (2004), MC-207,110 did not display 
any  advantageous  effect  on  efflux  of  erythromycin  or  streptomycin  by  the 
BpeAB-OprM pump in Burkholderia pseudomallei.  In the present study it was 
shown that MC-207,110 increased sensitivity to tigecycline in members of the 
Burkholderia cepacia complex by over 250 times, demonstrating that these 
microorganisms use efflux pumps as a resistance mechanism. The potency 
(MIC90 = 32 mg/L) of tigecycline in the absence of MC-207,110 was similar to 
the results published by Milatovic and coworkers (2003), but in the presence 
of  MC-207,110  the  MICs  decreased  significantly  (MIC90  =  1  mg/L).  Direct 
assessment of the efflux activity, using the sensitive fluorescent ala-nap assay Chapter 4: Discussion 
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system  demonstrated  a  correlation  between  efflux  activity  and  high  MIC 
values, and conversely the lower MICs of B. gladioli were correlated with low 
efflux pump activity.  Furthermore, combination therapy with MC-207,110 and 
tigecycline showed that they acted synergistically to reduce the viability of B. 
cepacia  biofilms.  Results  from  these  experiments  were  similar  to  results 
demonstrated by Kvist et al (2008). Combination therapy of tetracycline and 
the EPI 1-(1-naphthylmethyl)piperazine significantly reduced susceptibility of 
E. coli to tetracycline and also significantly reduced biofilm formation (Kvist et 
al,  2008).    Therefore,  these  results  indicate  a  dual  role  of  MC-207,100 
inhibiting efflux activity resulting in an increased sensitivity to drug treatment 
and reducing established biofilm biomass of this important CF pathogen. 
Overall,  the  data  supports  the  hypothesis  that  members  of  the  B.  cepacia 
complex utilise efflux pumps which have evolved to become integral to their 
natural physiological function, and which also confer inherent resistance to 
tigecycline.  However,  these  pumps  can  be  inactivated  using  inhibitors  to 
restore the activity of tigecycline. Whether EPIs can be used for combination 
therapy  with  tigecycline  in  CF patients  remains  to  be  seen.  Using  EPIs  in 
combination with tigecycline in CF patients may provide the opportunity for an 
antibiotic with unrestricted broad-spectrum antimicrobial activity. Of interest, 
EPIs are undergoing phase I trials in CF patients utilising an aerosol agent for 
administration and have been well tolerated in humans (Kvist  et al, 2008).  
Moreover, another potential benefit of EPIs in combination with an antibiotic is 
to  delay  the  development  of  resistance,  as  the  antibacterial  effects  are 
achieved at lower concentrations. Nevertheless, tigecycline is disappointing in 
the context of treating Gram-negative infections of the CF lung, yet given the Chapter 4: Discussion 
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potential immunomodulatory properties of the molecule then it may still have a 
role in CF management. 
Tigecycline is derived from tetracycline, which has been shown to have the 
capacity to modulate inflammatory processes, therefore, has the potential for 
suppressing  inflammation  of  the  CF  lung.  The  rationale  for  the  tigecycline 
concentrations used in this study was adapted from Golub  et al (2001), in 
which 20 mg/L oral doses of doxycycline were used, which was reported to be 
the  equivalent  to  a  therapeutic  dose  of 2.6  mg/L.    Initially,  human  derived 
A549 pulmonary epithelial cells and OKF6/TERT2 oral epithelial cells were 
used, and latterly human neutrophils were used in this study. Tigecycline was 
shown to have no toxicity in these cell types and was also shown to have no 
impurities. Low doses of tigecycline did not result in any significant reduction 
of  metabolic  activity  associated  with  either  cell  line,  which  was  critically 
important as damaged cells may have produced spurious data when in the 
progression  of  an  inflammatory  response  initiated  by  chronic  bacterial 
infections  (Laberge  et  al,  2004).  Tigecycline’s  possible  immunomodulatory 
properties  were  investigated  by  co-stimulating  human  derived  A549 
pulmonary epithelial cells and OKF6/TERT2 oral epithelial cells with 50 mg/L 
E.  coli  LPS  and  subinhibitory  doses  of  tigecycline.    The  rationale  of  the 
concentration  of  LPS  used  was  adapted  from  Krauker  et  al  (2002),  which 
used  100  mg/L  to  stimulate  peripheral  blood  mononuclear  cells  and 
pulmonary A549 epithelial cells during the investigation of pro-inflammatory 
cytokines  and  chemokines  (Krauker  et  al,  2002).    A549  epithelial  cells 
stimulated with 0–200 mg/L of LPS demonstrated a dose dependent increase 
in  IL-8.    Based  on  this  50  mg/L  of  LPS  was  used  throughout  subsequent Chapter 4: Discussion 
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investigations.  The data obtained from the immunological work produced for 
both  cells  lines  can  be  considered  to  be  spurious  in  some  cases.    Cells 
treated with tigecycline ± LPS displayed contradictory results producing both 
pro and anti-inflammatory effects.  A further point to add is the expression of 
mRNA after 4 hours represented higher expression levels of transcripts when 
compared to the 24 h time point (Figure3.12 A/B). This possibly results from a 
combination  of  one  or  more  of  the  following:  1)  the  optimal  time  point  for 
carrying  out  measurements  of  mRNA  were  not  identified  nor  used,  2)  the 
transient effect of the tigecycline and LPS on transcription, 3) the labile nature 
of mRNA molecules, i.e. they are rapidly degraded in cells 4) the compounds 
brought about opposite effects on transcription and mRNA stability.  Any of 
these  would  ensure  that  changes  in  mRNA  levels  did  not  match  protein 
expression  levels.  These  finding  are  not  in  line  with  evidence  reported  in 
literature  describing  the  anti-inflammatory  effects  of  the  tetracycline  based 
molecule  (Amin  et  al,  1996,  Salvatore  et  al,  2009).    Gene  and  protein 
expression of IL-8 from the A549 cell line was drastically lower than that seen 
in the literature when stimulated with LPS alone, Krauker (2002) displayed IL-
8 expression levels in excess of 5000 pg/ml after 24 hours when stimulated 
with E.coli LPS compared to the 2000 pg/ml expressed in these investigations 
from the A549 cell line (Standiford et al, 1990; Krauker et al, 2002). However, 
Ultra pure LPS do not always elicit an effect in epithelial cells (Hedlund et al, 
2001). Older preparations contain contaminants that assist LPS in stimulating 
TLRs    In  some  instances  treatments  with  tigecycline  alone  did  result  in  a 
significant  reduction  of  IL-8  from  both  cell  lines  (figure  3.13A/D  (p<0.05). 
However, these results may not prove fruitful as they represent tigecycline Chapter 4: Discussion 
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treatments independently of co-stimulation with LPS, which doesn’t represent 
a true model of infection.  Therefore these results prove to be of little benefit 
and do not display immunmodulatory properties associated with inflammatory 
disease.  Expression of IL-6 mRNA and protein serum levels were also low 
when expressed from treated A549 cells.  These findings are in line with an 
investigation  conducted  by  Yang  (2003)  which  reported  low  levels  of  IL-6 
mRNA  and  supernatant  protein  that  were  not  significantly  altered  following 
infection.    Figure3.10B  is  the  only  experiment  to  display  a  significant  pro-
inflammatory  effect  of  IL-6  mRNA  transcripts  following  from  co-stimulation 
with tigecycline and LPS at all three tigecycline concentrations compared to 
the LPS control.  However as with the IL-8 result these data was contradictory 
to changes in the levels of protein expression, which indicted marginal pro-
inflammatory  effects.    Taking  these  results  into  consideration  it  may  have 
proven advantageous to use an LPS derived from the common CF pathogens 
or  the  bacteria  themselves,  which  would  have  truly  reflected  an  accurate 
cytokine  and  chemokine  response  during  these  investigations.    B.  cepacia 
LPS and P. aeruginosa LPS are available for use in vitro.  B. cepacia has 
been shown to be 9 times more potent that P. aeruginosa LPS, inducing A549 
cells to significantly secrete IL-8 in a more potent manner compared to  P. 
aeruginosa (Hendry et al, 1999, Reddi et al, 2003).   
Cytokine and chemokine production by oral epithelial cells plays a major role 
in the recruitment and activation of professional phagocytes in the diseased 
periodontium. Inflammatory cytokines such as IL-6, IL-1b and IL-8 have been 
reported  to  be  higher  in  patients  with  periodontal  disease  than  in  healthy 
subjects (Cardoso et al, 2009).  In the present investigation the response of Chapter 4: Discussion 
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OKF6  cell  line  to  treatment  with  tigecycline  ±  LPS  appeared  to  generate 
spurious data.  As with the A549 cells, the OKF6 cell line produced pro- and 
anti-inflammatory responses to the same stimuli.  Figure 3.10A depicts IL-6 
mRNA  production  at  4  h,  showing  what  may  be  considered  to  be  a  pro-
inflammatory effect of low dose tigecycline, however when this was compared 
to the 24 h time point the high levels of IL-6 had reduced to the same level of 
expression as the LPS control. These contrasting results might be attributed 
to similar mechanisms as described above for the A549 cell lines. Levels of 
IL-8  production  recorded  in  figure3.13D  are  higher  than  those  reported  by 
Dongari-Bagtzoglo (2003).  The work conducted by Dongari-Bagtzoglo (2003) 
directly infected OKF6 cell line with whole cell Candida albicans for 24 h after 
which  approximately  500  pg/ml of  IL-8  was  produced.    In  contrast  results,  
obtained within this report by OKF6 cell treated with E.coli LPS was recorded 
at 1500 pg/ml.  This may be that greater numbers of cells were added too   
culture dishes in this study and or subtle differences in the culture conditions 
which had a stimulatory effect on cytokine production.    
 
Cells  treated  with  tigecycline  and  E.coli  LPS  recorded  similar  expression 
levels of IL-8, therefore, results suggested that low doses of tigecycline did 
not  exert  immunomodulation.    However  treatment  with  low  doses  of 
tigecycline alone appeared to have an anti-inflammatory effect by reducing 
the abundance of mRNA transcripts (figure 3.12D), and these are in-line with 
the reductions in the level of IL-8 recorded in figure 3.13D. The contradictory 
results in expression post-stimulation may be due to the choice of LPS.  It 
seems reasonable to speculate that treatment with a whole cell stimulus such Chapter 4: Discussion 
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as  with  a  bacterium  commonly  associated periodontal such  a  P.  gingivalis 
(Domisch  et  al,  2010)  may  have  been  a  better  choice.  The  immunology 
investigations in this study were somewhat disappointing, levels of IL-6 and 
IL-8 recorded in the results contained combination therapy of tigecycline and 
LPS  which  did  not  significantly  reduce  these  pro-inflammatory  mediators, 
displaying  low  levels  of  immunomodulation  for  both  cell  lines  investigated.  
However, the cell types were epithelial and not a professional immune cell, so 
work then progressed to investigate human neutrophils. 
 
Neutrophils are the origin of destructive enzymes in inflamed tissue, which are 
rapidly recruited to sites of inflammation, and are a key cell responsible for 
clearance  of  bacterial  infections  (Koller  et  al,  2009).    It  was  of  interest  to 
investigate if tigecycline may be able to reduce pro-inflammatory mediators 
produced  by  these  professional  immune  cells.  Tigecycline  displays  rapid 
intracellular penetration into neutrophils with concentrations reaching 20 – 30 
times higher when compared to extracellular drug concentrations (Ong et al, 
2005).  This may indicate why these low antimicrobial concentrations display 
immunomodulatory properties for neutrophil production of IL-8 and MMP-9, 
which in this study were reduced in a dose dependant manner. Indeed, an 
initial decrease was evident at 0.1 mg/L, below the 2.6 mg/L therapeutic dose 
used  in  Periostat®.  The  exquisite  nature  of  low  dose  concentrations 
tigecycline to modulate neutrophil derived IL-8 and MMP-9 is very intriguing, 
however this data can not be evaluated statistically due to the low number of 
replicates  in  this  study.    Neutrophil  derived  MMPs  degrade  all  protein 
components of the extracelluar matrix, studies have indicated that MMP-9 is Chapter 4: Discussion 
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up-regulated  in  the  bronchial  compartment  of  the  CF  lung  after  tissue 
inflammation, the increased expression of tissue remodeling enzymes at sites 
of inflammation are linked to impaired lung function (Roderfeld et al, 2009). 
Moreover, Gaggar and coworkers (2008) reported that MMP-8 and MMP-9 
are both involved in the production of peptide proline-glycine-proline, which 
acts as a strong ECM derived neutrophil chemoattractant and could contribute 
to neutrophil influx and airway damage in CF patients (Gaggar et al, 2008).  
As MMPs are viewed as key extracellular processing enzymes that regulate 
cell responses and signaling it is interesting that low doses of tigecycline may 
provided  a  beneficial  treatment  for  disease  symptoms  caused  by  MMPs 
(Kassim et al, 2007).  All MMPs are expressed at low levels in several types 
of  tissue,  even  in  the  absence  of  clinical  inflammation,  an  increase  in 
expression  levels  may  account  for  destruction  of  soft  tissue  in  the  clinical 
symptoms of CF (Dursun et al, 2001; Gaggar et al, 2008; Roderfeld et al, 
2009;  Wong  et  al,  2009).  Acute  pulmonary  infections  with  P.  aeruginosa 
induce MMP-7 and MMP-10, suggesting discrete roles for MMPs in airway 
epithelial cell regulation of immune responses, cell proliferation, cell death, 
and  other  process  key  to  initial  host  defences  against  bacterial  infections 
(Kassim et al, 2007).  Roderfield et al (2009) showed that serum derived from 
adult CF patients increased MMP-8 and MMP-9 expression, after antibiotic 
treatment  active  MMP-9  protein  levels  in  serum  were  significantly  reduced 
compared to a placebo control group (Roderfeld et al, 2009).  These findings 
support the in vitro observations reported in this present study, and may lend 
support  for  the  use  of  tigecycline  in  CF  and  other  chronic  inflammatory 
diseases. Chapter 4: Discussion 
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Periodontal disease displays similar inflammatory processes to CF given the 
complex  microbial  ecology,  clinical  symptoms  of  an  exacerbated  immune 
response, inflamed tissues linked to neutrophil activity and the presence of 
MMPs  often  found  in  oral  serum  samples  of  patients  suffering  from  oral 
inflammatory disease (Manicone and McGuire, 2008).  In the present study it 
was  shown  that  tigecycline  has  activity  against  several  key  periodontal 
pathogens growing as biofilms, supporting its potential dual role in periodontal 
therapy, similar to Periostat®. MMPs are involved in the physiological turnover 
of  periodontal  tissue  and  appear  to  be  involved  in  tissue  destruction. 
Neutrophil derived MMP-8 and MMP-9 are the main proteinases related to 
tissue destruction and remodelling events in periodontal tissue (Choi  et al, 
2004). Work by Garlet and coworkers (2006) showed that increased levels of 
IFN-y were directly associated with an increase in the expression of MMP-2 
and  MMP-9  from  24  h  until  15  days  of  infection  with  A. 
actinomycetemcomitans (Garlet et al, 2006). If tigecycline is able to reduce 
these  mediators  at  low  doses,  it  might  be  able  to  provide  some  relief  to 
patients who suffer the side effects of IL-8 induced neutrophil migration and 
excessive  neutrophil  activity  (Krakauer  2002).  Doxycycline  is  a  similar 
tetracycline  based  molecule  and  has  been  used  extensively  in  periodontal 
therapy (Alpagot et al, 2001/2006; Choi et al, 2004; Emingal et al, 2004a/b, 
Golub et al, 2001; Gu et al, 1996; Preshaw et al, 2004b).  A sub-antimicrobial 
dose of Periostat® (doxycycline) at 20 mg has been reported to be a safe and 
effective adjunct when taken twice daily for at least 3 months and up to 24 
months  in  a  randomized  placebo  controlled  clinical  trial  (Caton  and  Ryan 
2011).      Periostat®  is  currently  the  only  FDA  approved  inhibitor  of  MMP’s Chapter 4: Discussion 
 
119 
 
implicated  in  plaque-induced  pathologic  degradation  of  connective  tissue 
collagen of the supporting structures of the periodontium (Caton and Ryan 
2011).    Current  studies  indicate  the  potential  benefits  of  the 
immunomodulatory properties of SDD (Caton et al, 2001; Choi et al, 2004; 
Novak et al, 2002, Raza et al, 2006).  Emingil et al (2011) demonstrated that 
SDD can stabilise the inflammatory response by significantly reducing IL-6, 
TNF-  and  MCP-1  in  GCF  samples  from  patient  with  chronic  periodontitis 
(Emingil  et  al,  2011).    Therefore,  it  was  of  interest  to  evaluate  if  any 
immunomodulatory properties were associated with tigecycline.  As well as 
the reported immunomodulatory properties, SDD has also been shown to be a 
positive  inhibitor  of  MMPs  associated  with  chronic  inflammatory  disease.  
Currently  this  is  the  only  pharmacological  MMP-inhibitor  approved  by  the 
FDA,  and  has  shown  to  reduce  the  severity  of  chronic  periodontitis  whilst 
avoiding the long term side effects associated with tetracycline therapy (Lee 
et al, 2004). Thomas and coworkers (2000) demonstrated that long-term use 
of SDD does not lead to changes in antimicrobial susceptibility, demonstrating 
the potential positive role for this antibiotic (Thomas et al, 2000).  Choi and 
coworkers (2004) investigated the  use of SDD and reported that after 120 
days of scaling and root planning combined with SDD that this resulted in a 
reduction in both MMP8 and MMP9.  The group concluded that SDD therapy 
did  not  have  a  quantifiable  antimicrobial  affect  and  caused  no  apparent 
resistance,  indicating  that  this  type  of  therapy  can  be  used  safely  and 
effectively  (Choi  et  al,  2004).    Similarly,  Salvatore  and  coworkers  (2009) 
reported  that  administering  tigecycline  at  10  mg/kg  in  a  Mycoplasma 
pneumoniae  pneumonia  murine  model  significantly  reduced  key  pro-Chapter 4: Discussion 
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inflammatory cytokines and chemokines (IL-1β, IL-12, IFN-y and TNF-) over 
a  6  day  period  (Salvatore  et  al,  2009).    As  well  as  SDD,  oral  macrolide 
antibiotics  possess  immunomodulatory  activity  and  have  shown  to  down 
regulate prolonged inflammation. Indeed, randomised low dose azithromycin 
improved the clinical symptoms of CF lung disease prior to colonisation with 
P. aeruginosa (Fayon, 2006). 
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Conclusion 
In this study these experiments have demonstrated: 
  The  poor  antimicrobial  effects  of  tigecycline  against  planktonic  and 
sessile bacterial cells associated with inflammatory disease of the lung 
and oral cavity. 
  An increased sensitivity to these planktonic and sessile pathogens to 
tigecycline when incorporated with a competitive EPI. 
  The exquisite effects of EPI on disrupting biofilm biomass. 
  At  subinhibitory  concentrations  tigecycline  did  not  demonstrate  any 
significant  immunomodulation  of  pro-inflammatory  cytokines  and 
chemokines expressed by two clinical relevant cell lines. 
  However,  subinhibitory  doses  of  tigecycline  did  reduce  mediators 
involved with inflammation expressed by neutrophils. 
 
In  particular  this  study  had  demonstrated  the  effects  of  a  single  antibiotic 
compound, tigecycline, in combination with an EPI was investigated on single 
spp.  biofilms,  which  was  found  to  be  advantageous  in  reducing  antibiotic 
susceptibility.  Chronic  inflammatory  diseases  are  characterised  by  a 
persistent and dysregulated inflammatory response, which are associated with 
the  presence  of  established  bacterial  biofilms  and  an  exaggerated  host 
immune response.  An EPI in combination with tigecycline has demonstrated 
positive  effects  on  disrupting  biofilm  biomass  and  increasing  sensitivity  of 
bacterial spp. to tigecycline, thus indicating that EPIs could constitute to a new 
class of antibiotics.  To expand upon this microbiological work it would be of 
interesting to evaluate the effects of multiple EPI on multiple species biofilm.  Chapter 4: Discussion 
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This could encompass investigating the effects these compounds may have 
on  biofilm  formation,  relative  biomass  and  sensitivity  to  dual  and  triple 
combination  therapy  with  different  antibiotics.    Furthermore,  subinhibitory 
concentrations of antibiotic compounds could be utilised to determine if low 
doses  have  any  effect  of  QS  molecules  involved  in  biofilm  formation.  
Microarray assays could be employed to determine which genes are down or 
up regulated in the genome of these organisms and what part these may play 
in  biofilm  mediated  disease.    In  addition  to  these  microbiological  aspects, 
tigecycline at subinhibitory concentrations has been demonstrated to reduce 
pro-inflammatory  mediators  associated  with  neutrophils  (IL-8  and  MMP-9).  
Therefore, tigecycline could potentially be classed as an immune modulator, 
and may provide a beneficial treatment to reduce key MMPs associated with 
other inflammatory diseases.  
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